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Introduction
Lung cancer gives a high burden of disease to patients and is the leading cause of 
cancer mortality worldwide. The studies presented in this thesis address changes 
in treatment and survival in the Netherlands in the past 20 years. It further 
focuses on the possible use of DNA profiling in body fluids concerning prognosis 
and facilitating diagnosis of lung cancer.
The characteristics of lung cancer have changed in the past 20 years.1 About 87% 
of all lung cancer patients have non-small cell lung cancer (NSCLC); small cell lung 
cancer (SCLC) rates decreased to 10 to 15%. Since lung cancer is directly related 
to smoking, trends in incidence follow the smoking habits with a latency period 
of about 30 years.2,3 Following the significant decreased tobacco consumption in 
developed countries, the incidence of lung cancer in males is declining. In the 
Netherlands the age-standardized incidence rate (ESR) in males decreased from 
82 to 54 per 100,000 person years between 1989 and 2009 (www.ikcnet.nl). 
On the contrary, women increased smoking during the same period resulting in 
increased incidence rates in women from 11 per 100,000 in 1989 to 29 in 2009. 
However, among young women the incidence has started to flatten out expected 
to be followed by a further decreasing incidence in overall female lung cancer.4,5 
Nowadays the incidence of NSCLC in never smokers is increasing, especially in 
women. Possible causes are genetic, biologic and hormonal factors, and perhaps 
some factors related to the environment and lifestyle.6,7
Prognosis of lung cancer
In the past 20 years, the proportion of adenocarcinoma has increased and more 
patients presented with stage IV disease.5,8,9 Stage migration occurred as a result 
of improved staging techniques such as application of fluorodeoxyglucose-
positron emission tomography (FDG-PET) and endoscopic  ultrasound biopsies 
from mediastinal lymph nodes and also because of changes in the TNM (tumor, 
node, metastasis) classification system in 1997.10-14 With improved staging, 
patients with previous early stage disease will be upstaged (stage migration) 
which results in improved survival for all stage groups (Will Rogers phenomenon). 
Five-year survival in early stage lung cancer is 40 to 70% by surgical resection, 
but most patients are unresectable at the time of diagnosis. At the time of 
diagnosis, NSCLC is often locally or systemically advanced resulting in an overall 
5-year survival of only 16%.15 Median survival of SCLC is even worse and about 
1 to 2 years. In the past decades, refinements in surgery and perioperative care, 
radiotherapy and chemotherapy have been made enabling the combination of 
different modalities.16-18 In clinical trials with selected patients, mostly with a good 
performance status and younger age, these new modalities have shown slight 
improvements in 1- and 5-year survival. The question remains how these changes 
in treatment effected survival in daily practice with unselected patients. 
Prognostic factors predict survival independent of the treatment applied and 
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can classify patients as high or low risk. The most important prognostic factor is 
stage according to the TNM system.14,19 Larger tumors and involvement of higher 
lymph node disease have worse survival even in the same stage, which have led 
to revisions in the TNM system in 2009.20 Other prognostic factors include clinical 
aspects (e.g. gender, age, weight loss, cardiovascular disease), elevated lactate 
dehydrogenase levels, FDG-PET scan and pathologic aspects.21-26 Increasingly, 
multiple genetic and epigenetic alterations are under investigation as prognostic 
factors for survival.27-31 Cancer results from the accumulation of a variety of events 
in genes controlling cell growth and differentiation. (Epi)genetic changes consist 
of alterations in oncogenes such as KRAS (Kirsten rat sarcoma 2 viral oncogene 
homolog), p53 and EGFR mutations, hypermethylation of tumor suppressor 
genes such as  p16 and RASSF1A, loss of heterozygosity (LOH), and microsatellite 
alterations and deletions.32-38 Since many years free or circulating DNA in plasma 
or serum of (lung) cancer patients is under investigation for clinical relevance. 
Circulating plasma DNA is present in considerably higher concentrations in 
lung cancer patients compared with healthy controls or patients with benign 
disease.29,39 The increased circulating DNA concentration is thought to originate 
from cancer cells.40,41 Conflicting data have been reported about circulating DNA 
as a prognostic factor in NSCLC patients.42 Some studies showed a correlation 
between an elevated plasma DNA concentration and poor survival, whereas other 
studies did not report such a relationship. This might be explained by differences 
in patient selection, covering both NSCLC and SCLC, and different techniques for 
sample collection and DNA quantification. In SCLC patients, little is known about 
the prognostic value of circulating DNA. So far, sensitivity and specificity of (epi)
genetic changes has been limiting the clinical value due to the small number 
of cases and controls, the low frequency of (epi)genetic alterations, choice of 
appropriate markers and standardized methods.
Diagnosis of lung cancer
(Epi)genetic changes might also serve as useful diagnostic molecular markers. A 
long-standing goal of cancer researchers has been to develop tests that would 
facilitate earlier diagnosis and treatment of lung cancer and thereby decrease 
mortality and improve prognosis. Molecular analysis could be particularly useful 
for patients with advanced lung cancer in whom cytologic specimens, such as 
blood, bronchial washing or sputum, are often the only materials available. 
Flexible bronchoscopy is an essential step in the workup of lung cancer to establish 
a cytologic or histologic diagnosis. Washings, brushings and forceps biopsies 
are often combined to increase the diagnostic yield.43,44 The diagnostic yield of 
bronchoscopy increases in larger tumors and endoscopic visible tumors. The 
combined diagnostic yield in patients with endoscopic visible (central) tumors, 
mostly squamous cell carcinoma and small cell carcinoma, varies from 49% to 94%. 
In these patients, the diagnostic yields for washings and brushings are inferior to 
the yield of biopsies (52-77% and 71-91%, respectively). The combined diagnostic 
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yield in patients with endoscopic nonvisible (peripheral) tumors, mostly large 
cell and adenocarcinoma, is much lower and varies from 40% to 56%. In these 
patients the diagnostic yield of washings is similar to the yield for brushings and 
for biopsies and varies from 26 to 61%. The optimal timing of bronchial washing 
(ie whether before or after biopsy and brushing) is not clear. 
In case of a negative bronchoscopy, more invasive diagnostic procedures as 
transbronchial needle aspiration (TBNA), ultrasound guided endobronchial 
or endoscopic fine needle aspiration (EBUS-FNA or EUS-FNA), transthoracic 
needle aspiration (TTNA), mediastinoscopy or even thoracotomy are necessary 
to establish lung cancer diagnosis.44 If the diagnosis of lung cancer could be 
established easier, invasive diagnostic procedures could be prevented. Detection 
of (epi)genetic events in bronchial washings could facilitate in lung cancer 
diagnosis without additional (invasive) diagnostic procedures. Microsatellite 
alterations, KRAS mutations and EGFR mutations and expression can be found in 
washings of both visible and nonvisible lung tumors.45-48 In the last decade several 
studies showed that hypermethylated genes could be detected in bronchial 
washings.49-51 Hypermethylation of tumor related genes is a mechanism for 
silencing tumor suppressor genes.52,53 RASSF1A (Ras-association domain family 1A 
gene) methylation has been found in tumors of about 40% of NCSLC patients.35,54 
RASSF1A methylation was positively correlated with the amount of tumor cells in 
bronchial aspirates. Currently, in bronchial washings without cytologic or histologic 
diagnosis of malignancy, it is not clear whether methylation can be found.
Besides bronchoscopy, cytologic analysis of sputum can be used in the diagnostic 
workup of lung cancer. The average diagnostic yield of sputum cytology is 66% 
(range 22 to 98%) and increases with endoscopic visible tumors, the number of 
sputum specimens collected per patient, a large and/or high stage tumor (tumors 
greater than 2.4 cm in diameter) and histology (more in squamous cell carcinomas 
than in adenocarcinomas).43,55-57 Because tumor cells comprise only a minor 
fraction in most sputum samples, the amount of tumor DNA in sputum is likely 
to be low. It is not known if increased quantities of circulating or free DNA can be 
found in sputum. Free DNA may originate from malignant cells of lung cancer or 
upper airway cancer and also from inflammatory cells. Although not frequently 
used in daily practice due to the limited diagnostic yield, sputum analysis is under 
investigation in lung cancer screening programs.58,59
11
Introduction and outline 1
Outline of this thesis
In this thesis an overview of changes in treatment and survival of NSCLC and SCLC in 
the last 20 years in the Netherlands will be given. It further focuses how bronchial 
washings, RASSF1A methylation and circulating DNA facilitate in diagnosing lung 
cancer. Also the prognostic value of circulating DNA will be discussed. 
Chapter 2 describes changes in treatment in daily practice of unselected NSCLC 
patients in the Netherlands in the past 20 years. In these years, refinements in 
lung cancer therapy resulted in small improvements in 1-year and 5-year survival 
in  clinical trials. The effects of treatment changes to survival in daily practice 
are analyzed. Population-based data from the nationwide Netherlands Cancer 
Registry (NCR) are used. In chapter 3 changes in treatment in daily practice of 
SCLC in the Netherlands are described also using the population-based data 
from the NCR of a 20-year time period, and the effects of therapy on survival are 
analyzed in these patients.
The following chapters focus on the potential use of DNA profiling in body fluids. 
Chapter 4 reports the optimal timing of washing relative to biopsy and brushing 
in bronchoscopy. The diagnostic yields of washings before and after biopsy and 
brushings are compared. Also the cost-effectiveness of bronchoscopic procedures 
in patients with endoscopic nonvisible tumors is  studied. The different diagnostic 
strategies are assessed in terms of yield and costs. 
The yield of bronchoscopy in patients with endoscopic nonvisible tumors is 
usually modest. In these patients with negative bronchoscopy, the diagnostic 
value of RASSF1A methylation in washings is analyzed in chapter 5. RASSF1A 
methylation in patients is compared with controls. Also, the additional diagnostic 
value of combined RASSF1 methylation and KRAS mutation analyzes in washings 
is assessed. 
The presence of free DNA in sputum and its relationship to the presence of lung 
cancer is examined in chapter 6. The contribution of inflammatory cells to
the amount of free DNA in sputum is explored. To discriminate between tumor 
related free DNA and inflammation, hypermethylation of RASSF1A is assessed.
Free or circulating plasma DNA as a prognostic factor for survival is prospectively 
analyzed in NSCLC patients (chapter 7) and SCLC patients (chapter 8). Quantification 
of baseline circulating DNA is performed at the time of diagnosis by a real-time 
quantitative polymerase chain reaction (qPCR) targeting the human-globin gene.
The thesis concludes with a summary of the main results of our research in 
chapter 9 together with a general discussion and suggestions for future research.
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Abstract 
Introduction: Lung cancer is the leading cause of cancer mortality worldwide. We 
analyzed changes in treatment and their potential effect on survival of non-small 
cell lung cancer (NSCLC) patients in the Netherlands. 
Methods: All NSCLC patients diagnosed during 1989-2009 (n=147,760) were 
selected from the population-based Netherlands Cancer Registry. Differences 
in treatment over time were tested by the Cochran-Armitage trend test. The 
effects of sex, age, histology and treatment on relative survival were estimated in 
multivariable models. Follow-up was completed until January 1st 2010.
Results: Between 1989 and 2009, the proportion of younger patients (younger 
than  75 years) with stage I undergoing surgery increased from 84% to 89% and 
among elderly (75 years or older) from 35% to 49%; for stage II, this proportion 
decreased from 80% to 70% and remained about 25% in respectively younger 
and older patients. Adjuvant chemotherapy for stage II increased from 0% to 
24% in younger patients but remained <5% among the elderly. Chemoradiation 
increased from 8% to 43% among younger patients with stage III and from 1% to 
13% among elderly. In stage IV, chemotherapy in younger patients increased from 
10% to 54% and in elderly from 5% to 21%. Five-year relative survival of the total 
group increased from 14.8% to 17% (especially among females, younger patients, 
and within each stage), which could be partly explained by changes in treatment 
and better staging.
Conclusions: Over a 20-year period, application of therapy, which is currently 
considered as standard, has improved. This resulted in small improvements in 
survival within all stages.
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Introduction
Lung cancer is still the leading cause of cancer mortality worldwide. The incidence 
of lung cancer in males is declining in developed countries following the significant 
decreased tobacco consumption; in the Netherlands, the age-standardized 
incidence rate decreased from 82 to 54 per 100,000 person-years between 1989 
and 2009 (www.ikcnet.nl).1,2 Incidence rates in females increased from 11 per 
100,000 in 1989 to 29 in 2009 but are flattening out among young women.3 The 
majority (80 to 89%) of all lung cancers are non-small cell lung cancers (NSCLC).2,4 
The distribution of histology and stage has changed in the past 20 years, with 
an increase in the proportion of patients with adenocarcinoma and stage IV 
disease.5-7 Improved staging techniques such as application of fluorodeoxyglucose-
positron emission tomography (FDG-PET) and endoscopic ultrasound biopsies 
from mediastinal lymph nodes, combined with changes in the TNM (tumor, node, 
metastasis) classification system in 1997, resulted in stage migration.8-12 
At the time of diagnosis, NSCLC patients often have systemic disease resulting in an 
overall 5-year survival rate of only 16%.4,13 During the past 20 years, refinements 
in surgery and perioperative care, radiotherapy and chemotherapy have been 
made enabling the combination of different (new) modalities.14-16 In clinical trials 
with selected patients, mostly with a good performance status and younger age, 
these new modalities have shown slight improvements in 1- and 5-year survival. 
Standard treatment in the Netherlands is described in the “national guideline for 
staging and treatment of NSCLC” published in 2004 and was recently updated 
in 2011. The broad categories for treatment are surgery for stages I and II, 
chemoradiation for stage III and chemotherapy for stage IV (www.ikcnet.nl). The 
question remains how changes in patient selection for these treatment categories 
affected survival in daily practice. The period before the introduction of the 2004 
guideline (1989-2004) was used as start of our measurements. 
The aim of this study was to examine changes in treatment and survival of NSCLC 
patients in the Netherlands in the last 20 years, on a population-based level, 
according to stage, age group and sex. 
Patients and methods
Data collection
Population-based data from the nationwide Netherlands Cancer Registry was 
used which has complete national coverage and registers about 90,000 new 
cancer cases annually.17 Follow-up was calculated as the time from diagnosis 
to death or to January 1, 2010. The information on vital status was initially 
obtained from municipal registries and hospitals and from 1995 onwards from 
the nationwide population registries network. These registries provide virtually 
complete coverage of all deceased Dutch citizens. 
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For this study, all patients diagnosed with microscopically verified NSCLC (C34, 
ICD-O morphology codes 8010-14, 8020-22, 8030-33, 8046, 8050-78, 8082-84, 
8090, 8094, 8123, 8140-41, 8190, 8200, 8211, 8230-31, 8250-63, 8290, 8310, 
8323, 8333, 8430, 8470-90, 8550-51, 8560, 8562, 8570-75, 8972, 8980-82) during 
the period 1989-2009 in the Netherlands were included. Histology was classified 
as squamous cell carcinoma, adenocarcinoma and large cell carcinoma according 
to the World Health Organisation classification.18 A subgroup of other histologies 
consisted of adenosquamous and sarcomatoid tumors, among others. The study 
period was divided into four categories: 1989-1993, 1994-1998, 1999-2003, and 
2004-2009. Age was divided into three groups (<60, 60 to 74, and ≥75 years). 
The 6th edition of TNM classification was used for staging of lung tumors.19 The 
clinical TNM (cTNM) was used in trend analysis of primary treatment according 
to stage. For the cases where cTNM was unknown (11%), the pathological stage 
(pTNM) was added if known (5%). Primary treatment was classified as surgery 
(with or without chemotherapy and/or radiotherapy), thoracic radiotherapy, 
chemotherapy and thoracic radiotherapy (chemoradiation), chemotherapy alone 
and best supportive care (BSC). For survival analysis, pTNM was applied, and if 
pTNM was unknown, cTNM was used.
Statistical analysis 
The percentage of patients receiving certain types of treatment was calculated 
by age group and time period. Differences in treatment over time were tested 
by the Cochran-Armitage trend test. Relative survival was used as an estimation 
of disease specific survival and is calculated as the ratio of the observed rates 
in cancer patients to the expected rates in the general population.20 It reflects 
survival of cancer patients, adjusted for survival in the general population with 
the same age and gender distribution. Patients younger than 15 years and older 
than 95 years were excluded from survival analyses, as well as cases diagnosed 
by autopsy. Traditional cohort-based relative survival analysis was used for the 
period 1989-2003. As follow-up was available until January 2010, 5 years of 
follow-up was not available for the period 2004-2009, and therefore period-based 
relative survival analysis was conducted to obtain 5-year relative survival in this 
recent period.21 For stage I and II, 5-year relative survival was calculated, for stage 
III 3-year and stage IV 1-year relative survival. Survival trends were evaluated by 
a linear regression model and p<0.05 was considered as statistically significant. 
Multivariable relative survival analyses were performed to estimate relative excess 
risk (RER) of mortality for the periods of diagnosis adjusted for follow-up time, 
age, sex and histology, and stratified by stage. Treatment variables were added 
to investigate whether the effect of time period on survival could be explained 
by changes in treatment. The difference in RER is the part that was explained by 
changes in treatment. SAS software (SAS system 9.2, SAS Institute, Cary, NC) was 
used to perform the statistical analyses. 
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Table 1. Clinical and tumor characteristics of patients with non-small cell lung 
cancer by period of diagnosis.
*p-value: period 2004-2009 compared with 1989-1993 tested by the Chi-square test
cTNM, tumor, node, metastasis
Results
Patient characteristics
Patient characteristics are presented in Table 1. During the period 1989-2009, 
147,760 patients were diagnosed with NSCLC. The proportion of females more 
than doubled from 15% in 1989-1993 to 34% in 2004-2009. The median age has 
slightly increased among males from 69 years in 1989-1993 to 70 years in 2004-
2009 (p< 0.001) but remained stable at 64 years among females. Twenty-five 
percent of the patients was 75 years or older at the time of diagnosis. 
The proportion of patients with unknown stage decreased from 9% in 1989-1993 
to 2% in 2004-2009. After 1999, the proportion of patients with advanced disease 
(stage IV) increased from about 27% to 44% in 2004-2009, whereas the proportions 
of patients with stage I (about 27% to 20%) and III (about 37% to 30%) decreased. 
Over time, the proportion of nonsquamous cell carcinomas among male patients 
increased from 42% to 67%, independent of age and among females from 67% to 
81% with a stronger increase for those younger than 60 years (results not shown). 
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Trends in treatment 
Stages I and II 
Since 1989, the percentage of patients with stage I disease undergoing resection 
remained about 91% among those younger than 60 years and increased from 
77% to 82% among those aged 60-74 years (p < 0.001) and from 35% to 49% 
among patients aged 75 years or older (p < 0.001). Since 2003, the proportion of 
patients younger than 75 years receiving (neo-)adjuvant chemotherapy increased 
significantly, whereas (neo-)adjuvant radiotherapy decreased (Figure 1a). Among 
the elderly, (neo-)adjuvant chemotherapy or radiotherapy was hardly used. 
The percentage of patients receiving thoracic radiotherapy alone has slightly 
decreased since 1989 from 11% to 9% but remained over 30% for those aged 75 
years or older. 
Since 1989, the percentage of patients with stage II disease undergoing resection 
decreased from 89% to 79% among those younger than 60 years (p < 0.001), from 
71% to 62% among those 60-74 years (p < 0.001) and remained about 25% among 
patients aged 75 years or older. Since 1999, the proportion of patients younger 
than 75 years receiving (neo-)adjuvant chemotherapy increased significantly, 
but this treatment was hardly used among the elderly patients (Figure 1b). The 
proportion receiving (neo-)adjuvant radiotherapy has only decreased among 
those younger than 75 years (Figure 1b). The percentage of patients receiving 
thoracic radiotherapy alone has increased since 1989 from 17% to 21% (p < 0.01) 
and remained over 40% for those aged 75 years or older.
Figure 1. Changes in treatment for NSCLC according to stage and age.
1a – (neo-)adjuvant therapy stage I 
Yrs = years; CT = chemotherapy; RT = radiotherapy
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1b – (neo-)adjuvant therapy stage II 
Yrs = years; CT = chemotherapy; RT = radiotherapy
Stages III and IV
The introduction of chemoradiation for stage III was the most prominent change 
among young patients since 1997, followed by a similar change in the elderly since 
2000. In 2004-2009, chemoradiation for stage IIIA was applied in 56% of patients 
younger than 60 years and in 45% of patients aged 60-74 years, compared with 
12% and 5%, respectively, in the period 1994-1998 (Figure 1c). Chemoradiation for 
stage IIIB was applied in 41% of patients younger than 60 years in 2004-2009 and 
in 31% of patients aged 60 to 74 years, compared with 10% and 4%, respectively, 
in the period 1994-1998. Among patients aged 75 years or older, the proportion 
receiving chemoradiation in stage IIIA was 18% and 10% in stage IIIB in 2004-2009. 
Among those younger than 75 years, more patients received only chemotherapy 
than only radiotherapy and vice versa for those aged 75 years or older (results 
not shown). The proportion receiving chemotherapy alone increased significantly 
from 2% to 18% in stage IIIA and  from 4% to 26% in stage IIIB (p < 0.001 in all age 
groups), whereas the proportion receiving only (palliative) radiotherapy declined 
significantly over time from 64% to 18% in stage IIIA and from 60% to 15% in stage 
IIIB (p < 0.001 in all age groups).
Few stage III patients were eligible for surgery, whether or not combined with 
chemoradiation. The proportion of patients younger than 75 years undergoing 
surgery decreased from 25% to 15% in stage IIIA (p < 0.001 in all age groups) and 
increased from 8% to 10% in stage IIIB (p < 0.003 in all age groups). For patients 
aged 75 years or older this proportion decreased from 10% to 5% in stage IIIA (p 
< 0.001) and did not change in stage IIIB (3%, p = 0.45).
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1c – chemoradiation therapy stage III 
1d – chemotherapy stage IV
Yrs = years; CT = chemotherapy
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Since the mid-1990s, the proportion of stage IV patients receiving chemotherapy 
increased significantly among those younger than 60 years from 14% in 1989-
1993 to 63% in 2004-2009 and among those aged 60 to74 years from 5% to 47% 
(Figure 1d). Among patients aged 75 years or older this proportion increased 
significantly from 5% to 21% since 2000. 
Trends in survival 
Five-year relative survival for all patients improved significantly since 2005, from 
14.8% in 1989-93 to 16.1% in 2004-2009 (p = 0.003) and was 17.4% in the year 
2009. Five-year relative survival for females improved significantly from 14% in 
1989-1993 to 18% in 2004-2009 (p <0.001), whereas 5-year relative survival for 
males remained stable at 15%. Improvements in survival were observed among 
all age groups (<75 years from 16% to 18%, p = 0.01, and ≥75 years from 9% to 
11%, p = 0.001), and for patients with squamous cell carcinomas (from 17% to 
20%, p < 0.001) and nonsquamous cell carcinomas (from 11% to 14%, p < 0.001). 
Statistically significant improvements in relative survival over time were seen in 
stages I, III and IV (Figure 2). Survival rates according to treatment per stage and 
age group are presented in Figure 3. Relative survival was better for standard of 
care therapy in all stages and for all age groups. 
After adjustment for sex, age and morphology, the RER of dying within the first 
5 years after being diagnosed with stage I in 2004-2009 was significantly lower 
as compared with 1989-93 (RER = 0.62) (Table 2). After additional adjustment 
for changes in treatment over time, the prognostic effect for period of diagnosis 
became slightly smaller, but remained significant (RER=0.69). This was also true 
for patients with stage II and IIIA/B disease (RER stage II=0.84, after adjustment for 
treatment RER=0.78, and RER stage IIIA/B= 0.72, after adjustment for treatment 
RER = 0.88). For patients with stage IV NSCLC, the RER of dying within the first 
year after diagnosis in 2004-2009 was also significantly lower as compared with 
1989-1993 (RER = 0.69), but this effect disappeared after adjusting for changes in 
treatment over time (RER = 1.06).
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Figure 2. Trends in relative survival of non-small cell lung cancer according to 
stage and period of diagnosis. 
Figure 3. Relative survival of non-small cell lung cancer patients according to 
standard of care therapy per stage in 2004-2009. 
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Table 2. Multivariable relative survival analysis of NSCLC in the Netherlands, 
1989-2009.
RER = Relative Excess Risk of dying; 95% CI = 95% Confidence Interval
Discussion
This study showed that the proportion of NSCLC patients receiving the standard 
treatment according to the Dutch guidelines of 2004 increased significantly over 
time  compared with the period 1989-2004. Nevertheless, a substantial part of the 
patients did not receive this standard treatment, especially those aged 75 years or 
older. Five-year relative survival increased slightly since 2004/2005 for the whole 
group, and especially in females, younger patients and within each stage group, 
which could only partly be explained by survival benefits due to treatment.
In this study using nationwide population-based data of NSCLC patients, more 
female patients, more patients with advanced disease and nonsquamous cell 
carcinomas were diagnosed over time, as was observed elsewhere.1-4 The 
proportion of patients with unknown stage decreased, illustrating improvements 
in staging in recent years. 
Trends in treatment 
Surgery is the mainstay of curative therapy and offers the best chance for survival.22 
In accordance with other studies and conform (inter)national guidelines (www.
ikcnet.nl)23, we found in stage I that almost all patients younger than 60 years 
underwent surgery. This proportion increased over time for all age groups. (Neo-)
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adjuvant chemotherapy in stage I is not recommended except for clinical trials23, 
in our study only a minority received additional chemotherapy. Although in stage 
II disease surgery should also be the cornerstone of treatment, only 80% of the 
patients younger than 60 years underwent surgery and this proportion decreased 
over time. Resection of stage II tumors is often complicated by the size of the 
tumors or hilar lymph node metastases, combined with comorbidity: around 
50% of these patients have chronic obstructive pulmonary disease.23-27 Another 
explanation for the decreased resection rates might be stage migration from stage 
IIIA to IIB patients, including T3 tumors, after implementation of the 5th edition of 
the UICC TNM Classification in 1999. Resection rates may improve by centralizing 
surgical treatment and by implementing multidisciplinary meetings in which 
treatment strategies can be discussed.28,29 In the Netherlands, relatively and 
significantly more  patients received (neo-)adjuvant chemotherapy since 2004, in 
accordance with international observations.15,30-32 
In stage III disease combined chemo- and radiotherapy became standard of 
care since the early 1990s, replacing the use of radiotherapy alone.16,33,34 Earlier 
application of radiotherapy in concurrent schedules together with more accurate 
radiotherapy techniques have been achieved.16 Indeed, the proportion receiving 
chemoradiation among stage III patients increased considerably, although its use 
was still low (< 50%). Chemoradiation was used more frequently for stage IIIA 
than stage IIIB patients. This is probably due to the diversity of TNM subsets in 
stage IIIB including those in which radical radiotherapy cannot be applied, such 
as pleuritis carcinomatosa (T4 in this TNM staging and nowadays M1a in the 
new TNM staging of 2009) or large therapy fields including supraclavicular nodal 
disease (N3) and decreased pulmonary function.19,35  In advanced lung cancer 
(stage IV) palliative treatment aims to improve or maintain quality of life. Since the 
1990s, several studies have shown that platin-based palliative chemotherapy also 
prolongs survival and is indicated for patients with good performance status and 
recommended in current guidelines.36,37 In our study more than 50% of patients 
younger than 60 years received chemotherapy with remarkable increases since 
the late nineties. 
In line with other studies, about 25% of the NSCLC population was aged 75 years 
or older.13 In our study, elderly received less intensive treatment in every stage 
compared with younger patients, probably reflecting the higher prevalence 
of multiple co-morbid conditions, frailty and higher operative risks.26,27,38 Older 
lung cancer patients have approximately twice as many comorbidities compared 
with the general population, chronic obstructive pulmonary disease occurring 
most frequently. Video-assisted thoracic surgery-lobectomy, a new surgical 
technique, offers possibilities for the elderly, but was hardly applied in our study 
period because only few centers were offering such treatments.39 The use of 
(neo-)adjuvant chemotherapy in stage II was hardly implemented in elderly in 
the Netherlands as was also shown in a French study.31 The proportion of older 
patients receiving only radiotherapy did not change over time, being around 30% 
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in stage I and almost 50% in stage II, while being almost absent in younger patients. 
Similar proportions were observed in a Canadian population-based study.40 Since 
2002, there is an increased availability of stereotactic body radiotherapy, a new 
approach that delivers high radiotherapy doses in short treatment times. Since 
short-term treatment-related toxicity is low, stereotactic body radiotherapy is 
appealing for patients with comorbidity, bad performance status and elderly.41,42
The proportion receiving chemoradiation among older stage III patients increased 
considerably, although its use was still low (< 20%). Besides age, comorbidity 
and the diversity of TNM subsets in this stage are main obstacles for applying 
chemoradiation. In stage III clinical studies, less than 20% of patients aged 70 
years or older received chemoradiation.34 Therefore, it is not known whether the 
results of these studies can be extrapolated to elderly lung cancer patients.34 In 
our study, up to 40% of older stage III patients did not receive any therapy. In 
line with observations from other studies, elderly stage IV lung cancer patients 
received less chemotherapy than younger patients, although this proportion has 
started to increase (up to 24% in our study in 2009).43-45
Trends in survival 
In our study, 5-year relative survival of all patients with NSCLC together improved 
slightly since 2004/5 to 17.4%. Better compliance to treatment strategies with 
clinical service standards such as guidelines could have contributed to better 
survival at population level.46,47 With improved staging, patients with previous 
early stage disease will be upstaged (stage migration) which results in improved 
survival for all stage groups (Will Rogers phenomenon). The routine use of FDG-
PET and integrated PET-CT in the diagnostic workup of patients with early stage 
lung cancer since 2000 led to a stage-shift towards higher stages.8,9 Minimally 
invasive techniques such as esophageal or endobronchial endoscopic ultrasound 
enhanced the accuracy of mediastinal staging and may also have attributed 
to a stage-shift.11 However, in line with other studies, we observed a survival 
improvement for females and younger patients including all stages which would 
not be the case if only stage migration plays a role.27,48,49. We investigated whether 
the effect of time period on survival could be explained by changes in treatment 
by adding treatment variables in the multivariable analyses. Five-year relative 
survival of patients with stage I and II improved over time. This effect became 
slightly smaller but remained significant after adjusting for changes in treatment 
in stage I. This indicates that only part of this improvement can be explained 
by the higher resection rates. Improvements in pre-operative patient selection 
including multidisciplinary decision making, better staging, better anaesthestic 
techniques and peri- and postoperative care may have contributed to improved 
survival as well.28,50 Several non-randomized studies have shown improvement 
in overall survival by stereotactic body radiotherapy in stage I and this potential 
effect has to be awaited in our population-based data.41,42 Adjusting for changes 
in treatment in stage II did not affect 5-year relative survival corresponding to 
Chapter 2
30
the observed lower resection rates. The increased application of (neo-)adjuvant 
chemotherapy in this stage is expected to improve survival as was shown in 
several clinical studies and meta-analysis, but the effects on 5-year survival could 
not yet be detected.51
In the Netherlands, 3-year relative survival for stage IIIA and IIIB disease increased 
significantly over time, largely because of upstaging from stage IIIA to IIB patients 
after implementation of the 5th edition of the UICC TNM Classification, but also 
due to the use of chemoradiation, as shown in multivariable analyses. Recent 
studies indicate that overall survival might be further improved by administrating 
chemoradiation concurrently instead of sequentially but at the cost of more 
complications.34,52 Also patients with significant comorbidity or older age but 
with a good performance status can achieve similar survival rates as younger 
patients.33,53 Other studies showed that in a selected group of downstaged stage 
III patients including patients with N0 status after chemoradiation, lobectomy may 
further improve overall survival.54 In our study, 1-year relative survival for stage 
IV patients younger than 60 years doubled to 21% since 1989. These significant 
improvements over time disappeared after adjusting for the use of chemotherapy, 
implying that the increased use of chemotherapy could at least partly explain the 
improvements in survival. Previous platin-based studies showed improvement of 
survival and in the last years, applying newer chemotherapy regimens according 
to either histological subtype or targeted therapy aimed at somatic mutations 
in receptors or signal proteins (e.g., endothelial growth factor receptor) resulted 
in improved 1-year survival especially in adenocarcinomas.37,55,56 Further 
improvement in survival due to personalized treatment is expected in the near 
future. In our study, survival of older unselected stage IV patients was poorer 
compared with younger patients. Among selected patient groups, no survival 
differences were shown for fit elderly compared with younger patients, and 
therefore in the current guidelines chemotherapy is also recommended for the 
fit elderly.36,45,57 
The increased incidence of nonsquamous cell carcinomas due to changes in the 
WHO histological typing of NSCLC could also have contributed to improved survival. 
Among others, the current “non otherwise specified” category has been long time 
mixed in the large cell subgroup. Also, the incidence of NSCLC in never smokers 
is increasing, especially in women and nonsquamous cell carcinomas. Possible 
causes are genetic, biologic and hormonal factors, and perhaps some factors 
related to the environment and lifestyle.7,58 Furthermore, the better treatment 
strategies in adenocarcinomas might have resulted in improved survival. 
Our results are based on all NSCLC patients diagnosed in the past 20 years in the 
Netherlands but nevertheless have the following limitations: detailed information 
about diagnostic procedures, surgical techniques, thoracic radiotherapy dose, 
choice of chemotherapy and number of cycles, and comorbidity are not routinely 
recorded by the cancer registries. Therefore, the effect of newer treatment 
strategies can only be estimated.
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Conclusion
On a population-based level, adoption of standard of care treatment according to 
the current guidelines increased significantly over time to about 60% of the patients 
younger than 75 years. Although increased, this proportion was considerably 
less for those aged 75 years or older (about 20%). Improvements in application 
of standard therapy were most prominent since 2000 and the Dutch treatment 
guideline for NSCLC is started to get implemented. Over a 20-year period, small 
improvements in survival have been made for all stages despite improvement 
in staging and primary treatment. Since 2004/2005, five-year relative survival 
increased slightly for the whole group, especially in females, younger patients 
and within each stage group. Better adherence to therapy whenever possible may 
further improve survival besides personalized treatment strategies.
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Modest improvements of survival for patients with 
small cell lung cancer aged 45 to 59 years only, 
diagnosed in the Netherlands, 1989 to 2008
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Abstract
Introduction: Lung cancer was a major epidemic in the last decades; 10 to 15% 
of lung cancer consists of small cell lung cancer (SCLC). Several changes in the 
diagnostic and treatment procedures took place during the last 20 years. This 
paper focuses on trends in incidence, treatment and survival of SCLC observed 
since the 1990s.
Patients and methods: All cases with SCLC diagnosed in 1989-2009 in the 
Netherlands were included (n = 34,100). Follow-up was complete until January 
1st 2010.
Results: The proportion of patients with extensive disease (ED) increased from 
47% to 63%. The proportion of patients with limited disease (LD) receiving 
chemoradiation increased from 22% in 1989-2003 to 72% in 2004-2009 among 
those younger than  45-59 years, from 15% to 58% among those aged 60-74 years, 
and from 7% to 27% among those aged 75 years or older. Among patients with 
ED the proportion receiving chemotherapy remained stable over time (84%, 75% 
and almost 50% for the above mentioned age groups, respectively). Significant 
improvements in 1-year relative survival occurred for patients aged 45-59 years, 
but not for the other age groups. Relative survival has significantly increased for 
both stage groups.
Conclusion: Improved staging resulted in improved survival for both stage groups, 
whereas survival of the total group has only significantly improved for patients 
aged 45-59 years. The latter is possibly related with improved treatment strategies. 
As survival is still very poor, prevention of lung cancer remains important.
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Introduction 
Lung cancer is now the second most common cancer type in Dutch men and 
the third most common type in women (www.ikcnet.nl). In the 20th century, the 
increase in incidence and mortality of lung cancer in the Netherlands was so 
dramatic that it can be considered as a major epidemic.1 Although lung cancer 
mortality among men has been decreasing since the mid 1980s, the recent 
increase among Dutch women is one of the most prominent in Europe.2,3 
Ten to 15% of all lung cancer patients have small cell lung cancer (SCLC).4,5 SCLC 
is an aggressive tumor which is frequently metastasized at time of diagnosis; 
median survival time for patients with limited disease (LD) is approximately 23 
months and for those with extensive disease (ED) 8-12 months.6 Because SCLC 
is considered a disseminated disease, chemotherapy is the cornerstone in the 
treatment of both limited and extensive disease. Several studies have reported 
an improvement in survival following the introduction of chemotherapy in the 
1970s.4,7-10 Nowadays, standard treatment for patients with LD who have a 
good performance score consists of combined chemotherapy and radiotherapy, 
whereas for those with ED  chemotherapy alone is recommended (and depending 
on locoregional symptoms also thoracic radiotherapy). Due to the high probalility 
of brain metastases, prophylactic cranial irradiation (PCI) for patients with LD is 
recommended since the early 2000s.11 This results in better quality of life. Since 
the study of Slotman et al., PCI is also recommended for patients with ED.12 New 
treatment modalities resulted in small improvements in survival in clinical trials 
with selected patients, mostly with good performance status and younger age. 
The question remains how these changes in treatment effected survival in daily 
practice with unselected patients. This paper focuses on the trends in incidence 
of SCLC, treatment strategies and survival of unselected patients with SCLC in the 
Netherlands since 1989.
Patients and methods
Data collection
Population-based data were obtained from the nationwide Netherlands Cancer 
Registry (NCR), which started in 1989 and is maintained and hosted by the regional 
Comprehensive Cancer Centers (www.ikcnet.nl). The NCR is based on notification 
of all newly diagnosed malignancies in the Netherlands by the automated 
pathologic archive (PALGA). An additional source is the national registry of 
hospital discharge, which accounts for up to 8% of new cases. Information on 
patient and tumor characteristics is obtained routinely from the medical records 
6 to 9 months after diagnosis. The quality of the data is high, due to thorough 
training of the administrators and computerized consistency checks at regional 
and national levels. Completeness is estimated to be at least 95%.13 Follow-up of 
vital status of all patients was calculated as the time from diagnosis to death or 
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until January 1, 2010. The information on vital status was actively obtained from 
the municipal registries and from the database of deceased persons of the Central 
Bureau for Genealogy. 
For this study, all cases with primary SCLC (C34.0-C34.9 and morphology codes 
8041-8045) diagnosed in the period 1989 to 2009 in the Netherlands were included 
(n=34,100). Patients younger than 15 years and older than 95 years at diagnosis 
were excluded from the survival analysis, as well as cases diagnosed by autopsy. 
Treatment and survival were described for three age groups (45-59 years, 60-74 
years, and 75 years or older). The study period was divided into four categories: 
1989 to 1993, 1994 to 1998, 1999 to 2003, and 2004 to 2009. Clinical stage of 
disease was classified as limited (tumors confined to one hemithorax without 
pleural effusion and no distant metastases) and extensive (distant metastases 
in the contralateral chest or at distant sites and pleural effusion). Treatment of 
SCLC was classified as chemotherapy + thoracic radiotherapy (chemoradiation, CT 
+ RT), chemotherapy alone, and “no anticancer treatment/best supportive care 
(BSC)”. PCI  was described as proportion of those receiving chemotherapy.
Statistical analyses
Annual incidence and mortality rates for the period 1989 to 2009 were calculated 
per 100,000 person-years, using the annual mid-year population size as obtained 
from Statistics Netherlands. Rates were age-standardised to the European 
standard population (European Standardised Rates (ESR)). Changes were 
evaluated by calculating the estimated annual percentage change (EAPC) and the 
corresponding 95% confidence interval. To calculate this, a regression line was 
fitted to the natural logarithm of the rates, using the calendar year as regressor 
variable.
Stage at diagnosis and primary treatment was described as percentages per age 
group and time period. Differences between groups were tested with the chi square 
test. Relative survival was used as an estimation of disease-specific survival. It 
reflects survival of cancer patients, adjusted for survival in the general population 
with the same structure for age and gender. Relative survival is calculated as the 
ratio of the observed rates in cancer patients to the expected rates in the general 
population.14 Traditional cohort-based relative survival analysis was used for the 
period 1989 to 2003, which represents the real survival of patients diagnosed. 
Because follow-up for patients diagnosed in 2004 to 2009 was only available for 
a few years, period-based calculation of relative survival analysis was applied to 
generate the most up-to-date estimates for this period.15 Relative 1-, 3- and 5-year 
survival was estimated according to gender, stage, age and period of diagnosis. 
Survival trends were quantified as the mean annual percentage change within 
1989 to 2009 estimated by a linear regression model.
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Results
Patient characteristics
Table 1 shows the general characteristics of the patients. In the time period 1989 to 
2009 34,100 patients were diagnosed with SCLC: 23,299 (68%) males and 10,801 
(32%) females. The male-female ratio decreased from 3.7 in 1989 to 1993 to 1.4 
in 2004 to 2009. The median age at diagnosis increased from 68.1 to 69.3 years 
among males  (p<0.001) and from 63.6 to 65.6 years among females (p<0.001).
Table 1. Characteristics of patients with small cell lung cancer by period of 
diagnosis.
The proportion of patients with unknown stage decreased from 12% in 1989 to 
1993 to 4% in 2004 to 2009. Among those with known stage, the proportion of 
patients with ED at diagnosis was about 50% until the late 1990s, but increased 
to about 65% in 2004 to 2009 (Figure 1). The proportion of patients with LD was 
significantly higher among women (p<0.001). The proportional distribution of 
stage did not differ significantly between the age groups.
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Figure 1. Trends in stage distribution of SCLC in the Netherlands 1989 to 2009, 
according to gender.
Figure 2. Trends in age-standardised incidence rates (ESR) of small cell lung cancer 
(SCLC) in the Netherlands, 1989 to 2009.
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Trends in incidence
Figure 2 shows the trends in incidence of SCLC. The age-standardised incidence 
rate (ESR) of SCLC among men decreased from 19 per 100,000 in 1989 to 10 per 
100,000 in 2009. The estimated annual percentage change (EAPC) was –3.8%, 
95% CI=-4.1, -3.4. Among women the age-standardised incidence has increased 
from 4.3 to 7.0 per 100,000 (EAPC +2.6%, 95% CI= 2.3, 2.9). 
Trends in treatment strategies
Among younger patients with LD diagnosed in 2004 to 2009, the proportion 
receiving chemoradiation was considerably higher than among those aged 75 
or older (Figure 3A). Since the early 1990s the proportion of patients receiving 
chemoradiation has increased from 22% to 72% among those aged 45 to 59 years, 
from 15% to 58% among those aged 60 to 74 years, and from 7% to 27% among 
those 75 years or older (Figure 3B). In the meantime the proportion of patients 
receiving chemotherapy alone has decreased from 67% to 17% among those 
younger than 45 to 59 years, from 72% to 23% among those aged 60 to 74 years, 
and from 50% to 33% among those 75 years or older. Furthermore, the proportion 
of patients receiving best supportive care remained stable at 12%, 18% and about 
40% for those aged 45 to 59, 60 to 74, and 75 years or older, respectively. PCI was 
introduced in 1999 and increased to 69% in 2009 in patients aged 45 to 59 years 
who had received chemotherapy, 63% in those aged 60 to 74 years, and 42% of 
those 75 years or older.
Among patients with ED, the proportion receiving chemotherapy remained stable 
over time (84%, 75% and almost 50% for aged 45 to 59 years, 60 to 74 years, and 
75 years or older, respectively), but was considerably lower among those 75 years 
or older compared with younger patients (49% versus 84%, figure 3A). In contrast, 
the proportion receiving only best supportive care was 16% among patients aged 
45 to 59 years, but increased to 51% among those 75 years or older. Although 
PCI was not often applied to patients with extensive disease until 2006, 39% of 
patients aged 45 to 59 years who had received chemotherapy underwent PCI in 
2009. This proportion was 32% for those aged 60 to 74 years and 25% for those 
75 years or older.
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Figure 3A. Primary treatment of SCLC in the Netherlands (2004-2009) by stage 
and age
BSC=Best Supportive Care, CT=Chemotherapy, RT=Radiotherapy, PCI=Prophylactic Cranial 
Irradiation.  *Percentage of patients who received chemotherapy
Figure 3B. Trends in proportion chemoradiation for limited SCLC by age.
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Trends in survival
Relative survival for the whole group has only slightly improved, mainly since 
the mid-2000s. One-year relative survival increased slightly but not significantly 
from 26% to 32% for males (p=0.09, Figure 4A) and from 35% to 41% for females 
(p=0.14, Figure 4A), 3-year relative survival increased significantly from 5.5% to 
9.2% for males (p=0.001) and from 6.5% to 14% for females (p<0.001), and 5-year 
survival increased significantly from 3.6% to 6.8% for males (p<0.001) and from 
4.2% to 8.9% for females (p=0.001). 
When stratifying according to stage, 1-year relative survival for patients with LD 
was better in 2009 as compared with 1989 (61% versus 39% for males and 67% 
versus 51% for females, p<0.05). For those with ED, 1-year relative survival has 
slightly increased from 14% to 19% for males and from 20% to 27% for females 
(p<0.05).
One-year relative survival has only statistically significantly increased over time 
for patients aged 45 to 59 years (p=0.01, Figures 4B and 4C): from 37% to 51% 
among males and from 42% to 51% among females. For those aged 60 or older, 
survival has not significantly improved (p=0.10 and 0.08 for males and females 
aged 60 to 74 years, respectively, and p=0.49 and p=0.68 for males and females 
older than 75 years, respectively).
Figure 4. Trends in 1-year relative survival from SCLC in the Netherlands 2004-
2009, by gender and age.
A. By gender
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B. Males by age
C. Females by age
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Discussion
The incidence of SCLC further decreased among men but increased among 
women. There was a trend towards more extensive disease. Despite better 
staging techniques and increased use of new treatment modalities, survival of 
the total group of unselected patients with SCLC has only improved for patients 
aged 45 to 59 years.
Trends in incidence
Due to smoking behavior, the incidence of lung cancer among Dutch men 
increased  dramatically until the early 1980s, whereafter it has declined. In the 
mean time, there has been a shift from squamous cell and small cell carcinoma to 
adenocarcinoma.1,16 The incidence of lung cancer among women used to be much 
lower than the incidence among men, but since the early 1980s, the incidence 
among women (all histologic subtypes) has been increasing markedly to the point 
that the incidence rates for men and women have converged toward each other. 
However, recently the incidence of lung cancer, including SCLC, among young 
Dutch women has started to decrease.17 
Our study has shown that the proportion of patients diagnosed with ED has 
increased since the late 1990s. The same trend has been described in a recent 
study.16 This stage shift is probably caused by the introduction of improved 
diagnostic techniques, such as improved availability and quality of computer 
tomography (CT) and magnetic resonance imaging (MRI), and positron emission 
tomography (PET). In the Netherlands, brain CT with contrast or brain MRI is 
standard of care in order to determine whether or not  brain metastases are 
present. Introduction of PET-scanning differed between regions and took place 
between the early 1990s and the early 2000s. With the availability of these 
techniques the detection of previously occult distant metastases is facilitated, 
which has led to an upstaging from limited to extensive disease. The fact that 
overall 1-year survival of the total group did not significantly increase, but 1-year 
survival of both limited and extensive disease has improved over time, is in line 
with a stage shift.
Trends in treatment strategies
In our study the proportion of patients with LD receiving chemoradiation 
increased since the early 1990s, in accordance with the previously published 
studies. Clinical trials have shown that chemoradiation for LD has resulted in 
better local control and overall survival compared with chemotherapy alone.18-22 
After publication of a Norwegian study showing that a novel multimodal regimen 
is effective and well tolerated, concurrent chemoradiation became the new 
standard.23 Trials of newer chemotherapy variations have failed to produce a 
regimen that is clearly superior to the two-drug combination of etoposide and 
cisplatin, which has gradually become the standard of care for both limited and 
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extensive disease.18 Nowadays, standard treatment for LD SCLC in the Netherlands 
is cisplatin-etoposide (CE) combined with concurrent radiation therapy starting 
on the first day of chemotherapy course two. Sometimes cisplatin was substituted 
by carboplatin.24-26 
In our study, the application of PCI increased over time. The brain remains an 
important site of recurrence. With improved systemic treatment and longer 
survival the frequency of brain metastases increases. PCI substantially reduces 
the risk of brain recurrence, but the effect on survival has been debated.11, 27 In 
the Netherlands, PCI is applied in case of a partial response or stable disease to 
chemotherapy or chemoradiation. Because this is an observational study, we 
cannot evaluate the individual effect of PCI on survival in unselected patients. 
In accordance with previous studies28-34, elderly patients tend to receive less 
intensive treatment, either due to dose reductions of chemotherapy cycles or 
dose reductions/less frequent use of radiotherapy.28, 29, 32, 35-42 The less intensive 
treatment could be related to expected toxicity. Previous studies report 
inconsistent findings with regard to increased toxicity for elderly patients with 
SCLC and for those with serious comorbidity. Most of these studies were clinical 
trials and may therefore be biased due to trial eligibility criteria (most of them 
only including relatively healthy elderly patients). A recent publication from our 
group has shown that 60 to 75% of elderly SCLC patients who were selected for 
chemotherapy or combined chemoradiation developed toxicity, and two thirds of 
patients could not complete the full chemotherapy.34 
Trends in prognosis
Patients with SCLC have a very poor prognosis. In the majority of cases, death 
from recurrent disease occurs within 2 years of diagnosis. Previous studies have 
shown some progress in survival since the introduction of chemotherapy: 1-year 
relative survival rates improved from 18% in the 1970s to more than 30% in the 
1990s for patients up to 70 years and from 9% to almost 20% for the elderly.4,7,43-45 
We have shown that survival for the group of SCLC patients as a whole has not 
further improved since the early 1990s, except for age group 45 to 59 years since 
the mid-2000s. However, when stratifying according to stage, 1-year relative 
survival for both patients with LD and ED has improved, as was also found in an 
American study.46 The improvements in survival for each stage group with lacking 
improvement for the whole group might be explained by stage migration. The 
increased survival for patients aged 45 to 59 years might also be explained by 
improved treatment strategies.
In the Netherlands, prognosis was more favorable for females as compared 
with males. In Europe, 5-year survival for lung cancer in general used to be 
somewhat better for females than males.47 This might be due to the fact that 
SCLC was diagnosed earlier among females (results from this study), but also due 
the fact that the mean age of female lung cancer patients was lower than that 
of male patients. Furthermore, males have more tobacco-related comorbidity 
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than females.48 A favorable prognosis for females was also found for many other 
tumors.49, 50 
Relative survival of SCLC clearly decreased with increasing age. This was also 
found in previous studies.28, 35 The poorer prognosis among the elderly might be 
explained by several factors: an increased risk of mortality due to smoking-related 
comorbid conditions, such as chronic obstructive pulmonary disease (COPD), or a 
poor performance status, death due to a higher risk of complications of treatment 
(also related to decreased organ functions51, 52), or death of cancer due to less 
aggressive treatment. The latter could lead to a lower response rate and a higher 
recurrence rate among elderly patients. Previous studies indicated that prognosis 
for elderly patients with LD SCLC was not worse compared with younger patients 
after adjustment for differences in treatment modality, gender and comorbidity.29, 
30, 35, 38, 53 The fact that survival has not significantly improved for elderly patients 
in our study indicates that elderly did not yet benefit from improved treatment 
strategies.
Our population-based study made use of a large, high-quality population-based 
dataset to report on an unselected group of patients with SCLC, and this enables 
reliable comparison with other studies of unselected patients. Interpreting the 
prognostic effects of the different treatment modalities would be more difficult, 
though, since selection for treatment by the physician has played an important 
role. Caution is therefore warranted in comparing the outcomes with those from 
selected patient groups in clinical trials.
Conclusions
The diverging trends in incidence of SCLC between Dutch males and females 
followed the trends in smoking behaviour in the past. Improved staging resulted 
in improved survival for both stage groups, while survival of the total group 
has only significantly improved for patients aged 45 to 59 years. The latter is 
possibly related with improved treatment strategies. As survival is still very poor, 
prevention of lung cancer remains important.
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A prospective study of the timing and cost-
effectiveness of bronchial washing during bronchoscopy 
for pulmonary malignant tumors
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Abstract 
Introduction: The value of obtaining washings during fiberoptic bronchoscopy 
in the workup of lung cancer is controversial. Moreover, the optimal timing of 
washing relative to biopsy and brushing is not known. In this study the diagnostic 
yield of washings before and after biopsy and brushings were compared. The 
different diagnostic strategies were assessed in terms of yield and costs.
Patients and methods: A prospective study was performed from 2001 to 2003 in 
a secondary care medical centre. Two hundred twenty-one patients underwent 
flexible bronchoscopy and the diagnostic yield of washings before biopsy and 
brushing  (strategy I) and after biopsy and brushing (strategy II) specimens were 
assessed. Using the known probabilities and costings for various bronchoscopic 
procedures, the expected utility of a number of diagnostic strategies was 
estimated. 
Results: Patients (147 males and 74 females) were included in whom a definite 
cytologic or histologic diagnosis of pulmonary malignancy had been made. The 
diagnostic yield of strategy I was 72% for visible tumors and 36% for nonvisible 
tumors.  For strategy II it was 74% for visible tumors and in 42% for nonvisible 
tumors. The comparison of strategies I and II for both visible and nonvisible tumors 
revealed that 176 cases were concordant (80%); in 19 cases (9%) the cytologic 
analysis of washings in strategy I was positive for malignancy and negative in 
strategy II. In 26 cases (12%) washings in strategy II were positive and negative in 
strategy I (p = 0.37). An analysis of the diagnostic yield of both washings in visible 
tumors and nonvisible tumors showed no significant difference. In 13 patients, 
a diagnosis of malignancy was established only by washings (6%). Confining the 
laboratory investigations of washings or brush samples to those cases in which 
the  initial findings of the biopsies are negative (the two-stage procedure) is more 
cost-effective than examining all biopsy, brushing, and washing specimens. In 
patients with visible tumors, brushing or washing in addition to biopsy is equally 
cost-effective; in patients with nonvisible tumors, biopsy combined with washing 
is the preferred option.
Conclusions: No difference in the diagnostic yield could be demonstrated 
for washings before or after biopsies and brushings. Although the additional 
diagnostic yield of washing and brushing during bronchoscopy is relatively low, it 
is cost-effective to use these procedures in the diagnostic workup of patients who 
are clinically suspected of having a pulmonary malignancy.
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Introduction
To establish a cytologic or histologic diagnosis in suspected lung cancer, flexible 
bronchoscopy is an essential step in the workup. Washings, brushings and forceps 
biopsies are often combined to increase the diagnostic yield.1-5 The usefulness of 
obtaining washings is still subject to discussion.6 The diagnostic yield for washings 
in patients with endoscopic visible (central) tumors varies from 49% to 76% 
and is similar to the yield for brushings (52% to 77%) but is inferior to the yield 
of biopsies (71% to 91%).5,7-10 The diagnostic yield of washings in patients with 
endoscopic nonvisible (peripheral) tumors varies from 35% to 52% and is similar 
to the yield for brushings (26% to 52%) and for biopsies (36 % to 61%).5,7-10
The optimal timing of bronchial washing (i.e. whether before or after biopsy and 
brushing) is not clear. In some studies washings were obtained before biopsy and 
brush samples had been taken8-10, whereas in others washings were obtained 
after other specimens were collected.11-13 Only two abstracts have been published 
about the timing of bronchial washing at flexible bronchoscopy, but these have, to 
our knowledge, never been published as full articles.14,15
Of increasing interest are the costs of several bronchoscopic techniques to obtain 
a diagnosis in lung cancer. Since the diagnostic yield of washings and brushings 
is relatively modest, one might consider omitting these procedures altogether. 
However, the further diagnostic tests used if the above tests are negative are 
invasive, imposing a burden on the patient and incurring considerable costs. 
Therefore, even with a relatively low yield, washings and brushings may still be 
worthwhile. Govert et al concluded in his study that the collection of biopsies and 
either washings or brushings is probably the most cost-effective way to obtain a 
diagnosis in patients with endoscopic visible tumors.16 The cost-effectiveness of 
bronchoscopic procedures in patients with endoscopic nonvisible tumors has, to 
our knowledge, not been studied. 
The aim of this study was to compare the diagnostic yield of washings performed 
before and after brushings and biopsies during flexible bronchoscopy prospectively 
in patients with lung cancer. Also, different diagnostic strategies were assessed in 
terms of diagnostic yield and costs.
Patients and methods
From 2001 to 2003, a prospective study in a secondary care medical centre was 
performed to assess the diagnostic yield of washings before biopsies and brushings 
(strategy I) and after biopsies and brushings (strategy II). Patients suspected of 
lung cancer by signs, symptoms or chest radiograph findings underwent flexible 
bronchoscopy. An endoscopic visible tumor was defined as an exophytic tumor 
or mass, mucosal infiltration or submucosal lesion. An endoscopic nonvisible 
tumor was defined as a normal bronchial system or bronchial narrowing due 
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to extrinsic compression with normal mucosa. Of these, only patients in whom 
a definite cytologic or histologic diagnosis of pulmonary malignancy was made 
were included in the study. If the bronchoscopic techniques did not reveal a 
diagnosis, other techniques such as transbronchial needle aspiration (TBNA), 
transthoracic needle aspiration (TTNA), mediastinoscopy, thoracotomy and 
biopsies of extrapulmonary lesions were used. Specimens were considered to 
be adequate if alveolar macrophages and bronchial epithelial cells were present. 
The amount of alveolar macrophages may vary, but in most cases they are also 
present in the case of a centrally located tumor. Strictly speaking, the presence of 
alveolar macrophages may not be required, but they are a constant finding in the 
great majority of the washings.
Bronchoscopies were performed by the specialist pulmonologists or by pulmonary 
residents (under specialist supervision) of our hospital. Flexible bronchoscopes 
(model 1T240 (working channel 2.6 mm) and model 1T30 (working channel 2.8 
mm);  Olympus; Tokyo Japan) were used. Unless contraindicated, patients were 
pre-medicated with diazepam 5 mg orally and intramuscular atropine 0.25 mg, 30 
minutes before undergoing the procedure. Local anesthesia was achieved with 5 
ml of 4% lidocaine spray applied to the upper airway including the laryngeal area. 
This was followed with one to two aliquots of 2.5 ml of 4% lidocaine instilled over 
the mucosa of the trachea, carina and bronchial tree during bronchoscopy. 
Bronchoscopic technique
In patients with visible tumors, a first washing (washing I) was performed using 
20 ml of saline solution. When the recruitment was low after suctioning due to 
coughing or if the aliquot was to be separated for microbiologic analysis, another 
20 ml was injected and suctioned. After washing I, biopsies were taken of the 
suspected area and a brushing was performed. Finally, a second washing (washing 
II) of the suspected area was done, using the same technique as described for the 
washing I.
In patients with a tumor that was not visible through the bronchoscope, the 
washings were done in the corresponding segmental bronchus. After the washing 
I, brushing of the tumor was done under fluoroscopic guidance. If the brush could 
reach the tumor, biopsies were performed under fluoroscopic guidance. Then, 
washing II was performed.
The returned aspirates of the washings were fixed in a volume of 20 to 30 ml 
of fixation fluid (Fixcyt® containing 50% alcohol and 2% carbowax) and sent for 
cytologic examination. Biopsies were obtained using biopsy forceps (Olympus). 
Multiple biopsies (two to eight) were obtained for each patient, unless significant 
bleeding followed after the first specimen was obtained. The biopsy specimens 
were sent in neutral buffered formalin for histologic examination. Brushings were 
obtained with a disposable cytology brush (1.7 mm; Endomed; Phoenix, AZ). The 
material returned on the brush was spread on a slide, which was immediately fixed 
in 70% alcohol or by a spray fixative (Cerfix Spray Fixative® (containing 2-Propanol, 
Poly ethylene Glycol 300 and Acetone) Zschimmer and Schwartz, Inc; USA) and 
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the same brush was then agitated in about 20 to 30 ml of fixation fluid and cut 
off. The slides, rinsing fluid and brush were combined for cytologic examination 
of brushing.
Statistical and cost-effectiveness analysis
The level of agreement between both washings was tested with McNemar’s test, 
using a two-sided significance level of 0.05. A decision model was developed 
to analyze specimen collection strategies of bronchoscopy using appropriate 
software (DATA, version 4.0; Tree Age software; USA) (Figure 1).  The following 
three approaches were compared: 1. bronchoscopy with biopsy, brushing and 
washing; 2. bronchoscopy with biopsy and washing; 3. bronchoscopy with 
biopsy and brushing. The data were analyzed separately for patients with visible 
and nonvisible tumors. It was assumed that, in the case of negative findings, a 
diagnostic workup was continued by conducting a second bronchoscopy (in the 
case of a visible tumor) or by using more invasive diagnostic procedures, including 
thoracotomy, TTNA, mediastinoscopy, TBNA or biopsies of extrapulmonary 
lesions (Figure 2). Using the probabilities and costs of the various procedures, the 
expected value of a number of diagnostic strategies was estimated. Probability 
estimates were derived from our study; cost data were derived from the financial 
department of our hospital (Table 1). The expected value of an option is the sum 
of the values of all the outcomes of that option, with each value being weighed 
by the probability that the consequence will occur17.  In our model, confirming the 
diagnosis of lung cancer was used as outcome, while the monetary costs of the 
applied procedures were used as value inputs. 
In another decision model in the diagnostic workup, biopsy was routinely 
performed in combination with brushing and washing, but washing or brushing 
samples were submitted for laboratory investigations only in the case of a negative 
biopsy finding (two-stage procedure). The structure of this decision model is 
depicted in Figure 3. 
Figure 1. Structure of the decision model comparing three different bronchoscopic 
strategies in the workup of patients with clinically suspected lung cancer.
Positive = malignancy, negative = no malignancy
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Figure 2. Probability of using either of the invasive diagnostic procedures following 
a negative biopsy, washing and brushing to establish the diagnosis lung cancer.
* probability in visible tumor/ nonvisible tumor
TTNA = transthoracic needle aspiration; TBNA = transbronchial needle aspiration
Table 1. Unit costs of various diagnostic procedures and of out-patient visits, day 
care, and hospitalisation. 
*Data are presented as prices in Dollars
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Figure 3. Decision model reflecting the two-stage procedure: cytology of brushing 
(or washing) only in case of negative findings of biopsy and washing (or brushing).
Positive = malignancy, negative = no malignancy
Results
Two hundred eighty-one patients suspected of lung cancer underwent flexible 
bronchoscopy; 221 of these patients were proven to have a new pulmonary 
malignancy. The visible endobronchial abnormalities (137 patients) were exophytic 
tumor in 76 patients, mucosal infiltration in 37 patients, and submucosal lesions 
in 24 patients. Eighty-four patients had a nonvisible tumor. The study population 
had the following characteristics: mean age 65.6 years, range 38 to 88 years; 147 
men and 74 women.
The diagnostic results of visible and nonvisible tumors are presented in Table 2. A 
diagnosis was obtained from washing, biopsy, or brushing specimens from visible 
tumors in 129 of 137 patients (94%). The highest diagnostic yield was obtained by 
forceps biopsy in mass lesions (92%). The combined diagnostic yield of all three 
techniques for mass lesions was 97%, for infiltration was 92% and for submucosal 
lesions was 88%. A diagnosis was obtained from washing, biopsy, or brushing 
specimens from nonvisible tumors in 47 of 84 patients (56%). The diagnostic 
yield of washings before biopsies and brushings for specimens of visible tumors 
was higher than the yield for nonvisible tumors (72% and 36%, respectively). The 
same is true for the yield for performing washings after biopsies and brushings 
(74% and 42%, respectively). The yields of washing I and II for submucosal lesions 
was lower (58% and 54%, respectively) than the yield for exophytic tumor (75% 
and 84%, respectively) or for mucosal infiltration (76% and 62%, respectively).
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Table 2. Diagnostic yield of bronchoscopic visible and nonvisible tumors: different 
bronchoscopic techniques.
*Data are presented as number of patients (%)
 ‡Not in all cases biopsies and brushings were performed
The comparison of washing I and II for both visible and nonvisible tumors revealed 
that 176 cases were concordant (80%); in 19 cases (9%) cytologic analysis of 
washing I specimens was positive for malignancy, whereas that of washing II 
specimens was negative, and in 26 cases (12%) washing II specimens were positive 
whereas washing I specimens were negative (p = 0.37) (Table 3). There were no 
significant differences in the yields of washing I and II for visible tumors (p = 0.85) 
or for nonvisible tumors (p = 0.33). A diagnosis of pulmonary malignancy was 
made exclusively by washing specimens in 13 patients (6%) (Table 4). 
The appearance of washing II specimens was blood-stained in almost every 
patient (89%), and the appearance of washing I specimens was blood-stained 
in 29% of the patients. The analysis of washing II specimens was inconclusive 
due to poor cellularity in 5 patients and of washing I specimens in 1 patient. The 
amount of saline solution used to obtain both washings was 20 ml for 87% of the 
patients with visible tumors and 68% of the patients with nonvisible tumors. In 
the other cases, > 20 ml of saline solution was used because of low recruitment or 
separation for microbiologic analysis. In patients with visible tumors, there were 
no differences in diagnostic yield for both washings whether 20 ml or > 20 ml of 
saline solution was used. In patients with nonvisible tumors, the diagnostic yield 
for washings performed with > 20 ml of saline solution was higher (washing I, 
43%; washing II, 52%) than for those performed with only 20 ml (30% and 38%, 
respectively).
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Table 3. Comparison of diagnostic yield for washing I and washing II for both 
visible and nonvisible tumors. Note that discordant cases are italic.
*Data are presented as number of patients (%). Positive = malignancy, negative = no 
malignancy. P value = 1) 0.85, 2) 0.33, 3) 0.37, respectively
Table 4. Diagnosis of pulmonary malignancy made exclusively by washings.
*Data are presented as number of patients
Forty-five patients had a nondiagnostic bronchoscopy of whom 37 patients 
had a nonvisible tumor. In these patients, a diagnosis of pulmonary malignancy 
was established by a second bronchoscopy (2 patients), TBNA of mediastinal 
lymphadenopathy (6 patients), TTNA (21 patients), mediastinoscopy (2 patients), 
thoracotomy (6 patients) and biopsies of extrapulmonary lesions (e.g. liver, 
adrenal gland) (8 patients). 
The pathologic diagnosis of the pulmonary malignancies were squamous cell 
carcinoma (76 patients), adenocarcinoma (49 patients), undifferentiated large 
cell carcinoma (38 patients), small cell carcinoma (41 patients), carcinoid tumor 
(2 patients), bronchioloalveolar carcinoma (1), metastases from other organs (for 
example breast carcinoma, renal cell and other carcinomas) (14 patients). There 
were no false-positive results for the washings. Tumor cell type diagnoses were 
confirmed by resection samples in 28 patients who underwent thoracotomy.
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Costs of various strategies in relation to the diagnostic yield
The diagnostic yield in patients with visible tumors was 0.94, 0.88 and 0.88, 
respectively, for biopsy, washing and brushing; for biopsy and washing; and for 
biopsy and brushing. The probability of using an invasive diagnostic procedure 
after a negative first bronchoscopy is summarized in Figure 2, reflecting the 
frequency of these procedures in our series. It is assumed that either of these 
procedures establishes the diagnosis lung cancer. The expected values of the 
various approaches were $1,247, $1,223 and $1,223, respectively, favoring the 
performance of bronchoscopy with biopsy and either washing or brushing. In the 
two-stage procedure, the estimated probability of establishing the diagnosis of 
lung cancer at the initial stage of the diagnostic workup remained unchanged 
(0.94, 0.88 and 0.88 respectively). If no malignancy was found, the diagnosis of 
lung cancer was established by examining either brush or washing samples. The 
estimated probability of establishing the diagnosis after cytology of the brushing 
or the washing was in both cases 0.50. In the absence of a diagnosis after the 
first bronchoscopy, the same more invasive diagnostic options and associated 
probabilities were modeled. The expected value of these approaches was $1,247, 
$1,156 and $1,156, respectively, favoring the two-stage procedure, irrespective of 
whether brushing or washing was used in combination with biopsies. 
In patients with nonvisible tumors the diagnostic yields for the three approaches 
were 0.56, 0.46 and 0.49, respectively. The probability of using an invasive 
diagnostic procedure after a negative first bronchoscopy is summarized in Figure 
2, again reflecting the frequency of these procedures in our series. The expected 
value of the various strategies was $2,084, $2,243 and $2,178, respectively, hence 
favoring the approach employing bronchoscopy with biopsy in combination with 
washing and brushing. In the two-stage procedure, the estimated probabilities 
of establishing the diagnosis of lung cancer at the initial stage of the diagnostic 
workup remained unchanged (0.56, 0.46 and 0.49, respectively). The estimated 
probabilities of establishing the diagnosis after cytology of the washing samples 
(in the case of a negative test result after brushing) or cytology of the brushing 
samples (in the case of a negative test result after washing) was 0.12 and 0.18, 
respectively. In the absence of a diagnosis after the first bronchoscopy, the same 
more invasive diagnostic options and associated probabilities were modeled. 
The expected values of these approaches were $2,084, $2,043 and $2,051, 
respectively, favoring the approach employing bronchoscopy in combination with 
washing, followed by cytology of the brushing in case of an initially negative test 
result.
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Discussion
The aim of this study was to assess the diagnostic importance of the timing of 
washings at bronchoscopy in the investigation of patients suspected of having 
a pulmonary malignancy. The diagnostic yields in patients with visible tumors 
were 72% after washing I and 74% after washing II, which corresponds to values 
from other studies.5,7-10 The extent of visible tumors influences the diagnostic 
yield. The yields of washing I and II for submucosal lesions were lower (58% and 
54%, respectively) than for exophytic tumor (75% and 84% respectively) or for 
mucosal infiltration (76% and 62%, respectively). Other studies have given similar 
results18,19, although the definition of visible tumor varied between studies. The 
diagnostic yield for washings in patients with nonvisible tumors was lower than 
was expected (washings I, 36%; washing II, 42%). In other studies it varies from 
35% to 52%.5,7-10
When comparing washings before and after biopsies and brushings, no significant 
differences in the diagnostic yield could be demonstrated for both visible and 
nonvisible tumors in our study. In the literature, no comparable study has been 
found. Raymond et al described in an abstract no difference in diagnostic yield 
relative to the timing of washings for central tumors.14 In peripheral nonvisible 
tumors, however, the yield for bronchial washing after biopsy and brushing was 
significantly higher than the yield for washing before biopsy and brushing (45% 
and 25%, respectively). In another abstract regarding visible tumors, Scriven et al 
showed a higher yield for washings after biopsy and brushing.15
In 45 patients, the diagnostic yield of washing I was different from washing II. 
The question remains how the difference in yield between both washings can 
be explained. Arroliga and Matthay suggested that washings should be obtained 
after forceps and brush biopsies were performed to increase the diagnostic 
yield by referring to a study performed by Chaudhary et al.1,12 Chaudhary et al 
argued that more tumor cells would be freed after manipulation techniques were 
performed. However, Chaudhary et al. did not compare washings before and after 
biopsies and brushes in their study. The hypothesis of obtaining more tumor cells 
by manipulation was not confirmed in our study. Another explanation for the 
different results of washing I and washing II might be patient-related factors in 
bronchoscopy e.g. cooperation of the patient or coughing. Although washing II 
specimens were blood-stained in almost every patient, this did not complicate 
the cytologic examination by the pathologist. It is not clear if the amount of saline 
solution that was used to perform a washing influences the diagnostic yield. 
In our study, in patients with nonvisible tumors there was a trend for a higher 
diagnostic yield in washings performed with larger amounts of saline, i.e. > 20 ml. 
Pirozynski et al showed that performing a bronchoalveolar lavage using 200 ml of 
NaCl was a valuable diagnostic tool in detecting peripheral pulmonary malignant 
neoplasms, especially in adenocarcinomas, bronchioloalveolar carcinomas and 
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tumors exceeding 3 cm.20 Others have suggest that only small volumes, i.e. < 20 
ml, are required for a bronchial washing.6 
In 13 patients (6%), biopsies and brushings showed no malignancy and 
diagnosis of malignancy was established only by washings. Some studies have 
reported that adding bronchial washings to biopsies and brushings increases 
the diagnostic yield8,9,11-13,21,22, whereas others have reported no additional 
value of washings.7,19,23,24 The additional value of a washing as the only test 
providing a diagnosis varies from 1.5% to 5% in visible tumors and from 7.4% to 
9.5% in nonvisible tumors. In our study, the variation was 2.9% (washing II) to 
4.4% (washing I) in visible tumors, and 4.8% for both washings in patients with 
nonvisible tumors. 
In one study on the cost-effectiveness of adding a cytologic specimen, a modest 
increase in the sensitivity of fiberoptic bronchoscopy was found.16 Although the 
diagnostic yield of washing and brushing during bronchoscopy is relatively low, it 
is still cost-effective to use these procedures in the diagnostic workup of patients 
who are clinically suspected of having a pulmonary malignancy. Clearly, this is due 
to the relatively high costs associated with the more invasive procedures that are 
used in cases with negative biopsy, brushing and washing results. The two-stage 
procedure in which laboratory investigations of washing or brushing are confined 
to those cases where initial findings are negative could be a more cost-effective 
option. This is due to the saving of the costs of laboratory investigations, while at 
the same time fully exploiting the potential of these minimally invasive procedures 
at the expense of a delay in analysis of the cytologic specimens of about a day. 
The extra costs of administration for storing brushing - and washing samples were 
minimal (3.5 dollar) and were therefore neglected. In the two-stage procedure, 
biopsy combined with brushing or washing was equally cost-effective in patients 
with visible tumors; in patients with nonvisible tumors, biopsy combined with 
washing is the preferred option. 
Conclusion
The timing of washings during bronchoscopy in the diagnosis of lung cancer 
(before or after biopsy and brushing) does not influence the diagnostic yield. 
Although the diagnostic yield of washing and brushing during bronchoscopy is 
relatively low, it is cost-effective to use these procedures in the diagnostic workup 
of patients who are clinically suspected of having a pulmonary malignancy. 
Confining laboratory investigations of washing or brushing to those cases where 
initial findings of the biopsies are negative (the two-stage procedure) is more cost-
effective than examining all biopsy, brushing and washing specimens. In patients 
with visible tumors, biopsy combined with brushing or washing is equally cost-
effective. In patients with nonvisible tumors, biopsy combined with washing is the 
preferred option.
63
Timing and cost-effectiveness of bronchial washing 
4
References
1. Gasparini S. Bronchoscopic biopsy techniques in the diagnosis and staging of lung 
cancer. Monaldi Arch Chest Dis 1997; 52:392-398
2. Lundgren R, Bergman F, Ångström T. Comparison of transbronchial fine needle 
aspiration biopsy, aspiration of bronchial secretion, bronchial washing, brush biopsy 
and forceps biopsy in the diagnosis of lung cancer. Eur J Respir Dis 1983; 64:378-385
3. Saltzstein SL, Harrell JH, Cameron T. Brushings, washings or biopsy? Obtaining 
maximum value from flexible fiberoptic bronchoscopy in the diagnosis of cancer. 
Chest 1977; 71:630-632
4. Schreiber G, McCrory DC. Performance characteristics of different modalities for 
diagnosis of suspected lung cancer. Chest 2003; 123(suppl):115S-128S
5. Yick D, Kamangar N, Wallace JM. Review. Noninvasive bronchoscopic specimens in the 
diagnosis of lung cancer. J bronchol 2001; 8:301-308
6. Kvale PA, Bode FR, Kini S. Diagnostic accuracy in lung cancer: comparison of techniques 
used in association with flexible fiberoptic bronchoscopy. Chest 1976; 69:752-727
7. Lam WK, So SY, Hsu C, et al. Fibreoptic bronchoscopy in the diagnosis of bronchial 
cancer: comparison of washings, brushings and biopsies in central and peripheral 
tumours. Clin Oncol 1983; 9:35-42
8. Mak VHF, Johnston IDA, Hetzel MR, et al. Value of washings and brushings at fibreoptic 
bronchoscopy in the diagnosis of lung cancer. Thorax 1990; 45:373-376
9. Wong PC, Lee J, Lam FM, et al. Fibreoptic bronchoscopy in the diagnosis of lung 
cancer. Monaldi Arch Chest Dis 1999; 54:394-398
10. Buccheri G, Barberis P, Delfino M. Diagnostic, morphologic and histopathologic 
correlates in bronchogenic carcinoma: A review of 1045 bronchoscopic examinations. 
Chest 1991; 99:809-814
11. Chaudhary BA, Yoneda K, Burki NK. Fiberoptic bronchoscopy. Comparison of 
procedures used in the diagnosis of lung cancer. J Thorac Cardiovasc Surg 1978; 
76:33-37
12. Williams T, Bowie PES. The bronchoscopic diagnosis of lung cancer. A prospective 
correlation between the bronchoscopic appearances and cytology and biopsy results. 
J bronch 2000; 7:295-300
13. Raymond NJ, McLeod S, Thornley PE. Timing of bronchial washing at fibrebronchoscopy 
improves the diagnostic rate of primary bronchial carcinoma (abstract). Thorax 1991; 
46:289P
14. Scriven NA, MacFarlane JT, Clelland CA. Bronchial washings – when should we do 
them (abstract)? Thorax 1999; 54(suppl 3):84
15. Govert JA, Kopita JM, Matchar D, et al. Cost-effectiveness of collecting routine 
cytologic specimens during fibreoptic bronchoscopy for endoscopically visible lung 
tumor. Chest 1996; 109:451-456
16. Hunink MG, Glasziou PP. Decision making in health and medicine. Cambridge, 
Cambridge University Press, 2001
17. Jones AM, Hanson IM, Armstrong GR, et al. Value and accuracy of cytology in addition 
to histology in the diagnosis of lung cancer at flexible bronchoscopy. Resp med 
2001;95:374-378
18. Karahalli E, Yilmaz A, Türker H, et al. Usefulness of various diagnostic techniques 
during fiberoptic bronchoscopy of endoscopically visible lung cancer: should cytologic 
examinations be performed routinely? Respiration 2001; 68:611-614
19. Pirozynski M. Bronchoalveolar lavage in the diagnosis of peripheral, primary lung 
cancer. Chest 1992;102:372-374
Chapter 4
64
20. Jay SJ, Wehr K, Nicholason DP, et al. Diagnostic sensitivity and specitifity of pulmonary 
cytology: comparison of techniques used in conjunction with flexible fiberoptic 
bronchoscopy. Acta Cytol 1980; 24:304-312
21. Stringfield JT, Markowitz DJ, Bentz RR, et al. The effect of tumor size and location on 
diagnosis by fiberoptic bronchoscopy. Chest 1977; 72:474-476
22 Chopra SK, Genovesi MG, Simmons DH, et al. Fiberoptic bronchoscopy in the diagnosis 
of lung cancer. Comparison of pre- and post-bronchoscopy sputa, washings, brushings 
and biopsies. Acta cytol 1977; 21:524-527
23. Solomon DA, Solliday NH, Gracey DR. Cytology in fiberoptic bronchoscopy: comparison 
of bronchial brushing, washing and post-bronchoscopy sputum. Chest 1974; 65:616-
619
                       Chapter   5
van der Drift MA, Prinsen CFM, Knuiman GJ, Janssen JP, 
Dekhuijzen PNR, Thunnissen FBJM. 
Chest 2012;141: 169-175
Diagnosing peripheral lung cancer: the additional value 
of RASSF1A methylation and KRAS mutation analyses 
in washings in nondiagnostic bronchoscopy
Chapter 5
66
Abstract 
Introduction: The diagnostic yield of bronchoscopy in patients with endoscopic 
nonvisible (peripheral) tumors varies from 40% to 56%. Increasingly, molecular 
markers in bronchial washings are being investigated to improve the diagnostic 
yield. The aim of this study was to analyze the diagnostic value of Ras 
associated domain family 1A gene (RASSF1A) methylation analysis in washings 
in nondiagnostic bronchoscopy in the analysis of patients with suspected lung 
cancer who had peripheral tumors. Furthermore, the additional diagnostic value 
of Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutations with RASSF1 
methylation was analyzed.
Patients and methods: From a prospectively collected series, 129 lung cancer 
patients and 28 controls were analyzed retrospectively regarding the methylation 
status of the promoter region of the RASSF1A gene by quantitative methylation-
specific PCR (qMSP) and KRAS point mutations by using the sensitive Point-EXACCT 
method.
Results: A total of 40% of the lung cancer patients had peripheral tumors, and 
17 patients had a nondiagnostic bronchoscopy. In these patients, RASSF1A 
methylation was detected in the washings of 4 patients (24%), and KRAS 
mutations were detected in the washings of  2 patients (12%). In total, 29% of 
the false-negative or doubtful cytology results were accompanied by RASSF1A 
methylation or KRAS mutation results that were highly suggestive of malignancy. 
The proportion of RASSF1a methylation was significantly higher in central and 
larger tumors. No relevant RASSF1A methylation was detected in control samples. 
Conclusions: Our data suggest that the molecular analysis of 2 biomarkers in 
nondiagnostic bronchial washings may better guide diagnostic procedures in 
patients with suspected lung cancer.
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Introduction
Flexible bronchoscopy is an essential step in the analysis of lung cancer. Washings, 
brushings and forceps biopsies are often combined to increase diagnostic yield.1-3 
The combined diagnostic yield of patients with endoscopic visible (central) 
tumors, mostly squamous cell carcinomas and small cell carcinomas, varies from 
49% to 94%. The combined diagnostic yield of patients with endoscopic nonvisible 
(peripheral) tumors, mostly large cell carcinomas and adenocarcinomas, is lower, 
varying from 40% to 56%. In cases of nondiagnostic bronchoscopy, supplementary 
diagnostic procedures, such as transbronchial needle aspiration(TBNA), 
ultrasound-guided endobronchial or endoscopic fine needle aspiration (EBUS-
FNA or EUS-FNA), trans-thoracic needle aspiration (TTNA), mediastinoscopy 
or even thoracotomy, are necessary to establish a lung cancer diagnosis.3 If 
the diagnosis of lung cancer could be established more easily, then (invasive) 
supplementary diagnostic procedures could be avoided. The detection of (epi)
genetic abnormalities in bronchial washings may enhance lung cancer diagnosis 
without the need for (invasive) supplemental diagnostic procedures. 
Increasingly, molecular markers in bronchial washings and bronchoalveolar 
lavage (BAL), including microsatellite alterations and epidermal growth factor 
receptor (EGFR) mutations, have been under investigation to improve the 
diagnostic yield of bronchoscopy.4-8 In the past decade several studies have 
shown that hypermethylated genes could be detected in bronchial washings.9-14 
Hypermethylation of tumor-related genes is a mechanism for silencing tumor 
suppressor genes.15,16,17 RASSF1A (Ras-association domain family 1A gene) has a 
tumor suppressor function and RASSF1A methylation has been found in the tumors 
of approximately 40% of non-small cell lung cancer (NCSLC) patients.18,19,19,20 In 
bronchial aspirates, RASSF1A methylation was present in 18% to 46% of NSCLC 
patients compared with 0% to 4% of patients without cancer.11,12,14,21,22 RASSF1A 
methylation was positively correlated with the number of tumor cells in bronchial 
aspirates. Currently, in bronchial washings with no cytologic diagnosis of 
malignancy, it is not clear whether methylation can be detected.
Activation of the Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) by 
point mutations in codon 12 occurs in approximately 30% of pulmonary 
adenocarcinomas. In previous reports, the diagnostic value of KRAS mutations 
in bronchoalveolar lavage fluids is limited due to the relatively low prevalence of 
KRAS mutations in NSCLC.23,24,25
The aim of this study was to analyze the diagnostic value of RASSF1A methylation 
in the bronchial washings of patients with peripheral tumors suspected of lung 
cancer without diagnosis after bronchoscopy. The additional diagnostic value of 
combined RASSF1A hypermethylation and KRAS mutation analyses was assessed.
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Patients and methods
Patients
From a prospective lung cancer study endobronchial washing samples were 
collected from 2001 to 2003 and retrospectively analyzed for the diagnostic value 
of KRAS mutations and RASSF1A methylation.2 A total of 281 patients suspected of 
having lung cancer by symptoms or chest X-rays underwent flexible bronchoscopy. 
Of these, 221 patients were diagnosed with (lung) cancer. Patients were included 
in this study when sufficient material was available for molecular analysis (129 
cancer patients and 28 controls).
Patients in whom no lung cancer was found after analysis served as controls to 
assess methylation status. The mean follow-up time of the controls was 6.9 years 
(range: 6-8 years); none of them developed (lung) cancer. Approval of the local 
ethics committee was obtained. Institutional guidelines do not require written 
permission because no supplementary procedures were performed and clinical 
data were anonymized.
Bronchoscopic technique
The routine diagnostic procedure consisted of bronchial brushing and washing for 
cytologic examination, and biopsies for histologic examination. Peripheral tumors 
were defined as endobronchial nonvisible tumors, including a normal bronchial 
system or bronchial narrowing due to extrinsic compression with normal mucosa. 
In cases of peripheral tumors, brushings and biopsies were performed under 
fluoroscopic guidance in the corresponding segmental bronchus. Bronchial 
washings were performed with 20 to 30 ml saline in the segmental bronchus 
that had been identified endoscopic or radiographic to contain the tumor. The 
returned aspirates of the washings were fixed in 20-30 ml of fixation fluid (Fixcyt® 
containing 50% ethanol and 2% Carbowax) and sent for cytologic examination. 
DNA was isolated from the cytology samples as described previously26 and 
RASSF1A hypermethylation and KRAS mutation analyses were performed. 
RASSF1A methylation analysis 
A maximum of 1 μg of human DNA that was purified from the cytology samples 
was bisulfite treated using the EZ DNA Methylation –Gold kit (Zymo Research, 
Baseclear, Leiden, the Netherlands). As a positive control, in vitro methylated 
human genomic DNA (M.Sss1, New England Biolabs, Westburg, the Netherlands) 
was used. In bronchial washings, the methylation status of the promoter region 
of the RASSF1A gene was determined by quantitative methylation-specific PCR 
(qMSP) as described previously.27 In short, methylated human DNA was quantified 
on a LightCycler 1.5 instrument after absolute quantification using the second 
derivative maximum method (Roche Diagnostics, Almere, the Netherlands). 
MyoD1 was used as a control gene. All assays were performed at least twice. 
When two results were the same, the outcome was considered to be conclusive. 
69
Molecular diagnosis of peripheral lung cancer
5
In cases of inconclusive outcomes the  assay was repeated once more, which was 
decisive for the outcome.
KRAS mutation analysis 
KRAS analysis was performed according to the Point-EXACCT method with a 
modification that included binding of the capture probe from the microtiterplate 
to a streptavidin-coated microarray glass slide.28,29 The oligonucleotide sequences 
for the 1st and 2nd nucleotide of the triplet of codon 12 and PCR primers were as 
described previously 28 and supplied by Eurogentec (Seraing, Belgium). A16-atom 
spacer arm was used to attach the biotin group to the oligonucleotides, whereas 
a 12-atom spacer arm was used in the attachment between the digoxigenin (DIG) 
and the penultimate 3’ terminal nucleotide. Streptavidin-coated glass slides were 
purchased from Dot Diagnostics, the Netherlands. Mutant and wild type capture 
probes for KRAS codon 12 were printed in triplicate. Capture probe spotting on 
the slide, PCR, hybridization, ligation and immunodetection were performed as 
described previously. Control samples were used each day and consisted of PCR 
products derived from 1 μg template samples with 25% and 4% KRAS mutated 
A549 or SW480 tumor cells, respectively, and negative control products. Ligation 
control spots were available on each processed slide for the wild type KRAS 
sequence. 
Statistical analysis
Data were analyzed with SPSS/PC+, version 16.0 (SPSS, Inc., Chicago, IL). 
Descriptive statistics were used for clinical characteristics and comparisons were 
performed by t-tests or Chi-square tests, as appropriate. A p-value of ≤ 0.05 was 
regarded as significant. 
Results
Baseline characteristics
The clinical characteristics of 129 patients and 28 controls are summarized in 
Table 1, 70% were men. Fifty-one patients had peripheral tumors. Pathologic 
analysis showed squamous cell carcinoma in 37% of the patients and non- 
squamous cell carcinoma in 45%. Mixed tumors consisted of NSCLC and small cell 
lung cancer (SCLC) cells. In 17 of the patients, no cytologic or histologic diagnosis 
of lung cancer was made by bronchoscopy. All cytologic samples were adequate. 
Two samples consisted of atypical cells and were interpreted as nondiagnostic 
after additional diagnostic procedures were performed. Additional diagnostic 
procedures to establish a lung cancer pathology diagnosis consisted mostly of 
TTNA (59%); the other diagnostic procedures are shown in Table 2. The biopsies 
of the extrapulmonary lesions consisted of a thoracentesis of the pleural fluid 
(pleuritis carcinomatosa) and a biopsy of an epidural tumor. 
The diagnostic yield of the histologic and cytologic bronchoscopic analysis from 
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central and peripheral tumors is presented in Table 3. As expected, the diagnostic 
yield of central tumors was significantly higher than that of peripheral tumors 
for both histologic (85% and 37%, respectively) and cytologic (100% and 47%, 
respectively) analyses. In 22% of patients with peripheral tumors, no biopsies 
were performed.
Table 1. Clinical and tumor characteristics of lung cancer patients and controls. 
SCC = squamous cell carcinoma; AC = adenocarcinoma; BAC = bronchioloalveolar 
carcinoma; LCC = large cell carcinoma; SCLC = small cell lung cancer 
Table 2. Additional diagnostic procedures to establish lung cancer diagnosis when 
bronchoscopy was negative (n = 17). 
RASSF1A methylation and KRAS mutation in bronchoscopic samples
The results of the RASSF1A methylation and KRAS mutation analyses in patient 
washings are presented in Table 3. RASSF1a methylation was higher in central 
tumors (50%) than in peripheral tumors (31%) (p = 0.03). The median methylation 
ratio was 195.4 (range: 0.64–74,949.6) for central tumors and 24.9 (range: 0.3–
1,319.2) for peripheral tumors (p = 0.003). The number of KRAS mutations did 
not differ between central tumors (9%) and peripheral tumors (6%) (p = 0.78). In 
6 patients (5%), both RASSF1A methylation and KRAS mutations were found, 4 in 
central tumors and 2 in peripheral tumors.
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Table 3. Diagnostic yield of histologic, cytologic and biomarker analysis from 
central  and peripheral tumors.
KRAS= Kirsten rat sarcoma 2 viral oncogene homolog; RASSF1A = Ras associated domain 
family 1A gene. Data are presented as No. (%).
In 17 patients with nondiagnostic bronchoscopies, RASSF1A methylation was 
detected in the washings of 4 patients (24%), or 8% of the overall group of 51 
patients with peripheral tumors. The median methylation ratio in this group was 
7.6 (range, 1.4-28.6). In 2 patients with nondiagnostic bronchoscopies, KRAS 
mutations (both TGT mutations in codon 12) were detected in the DNA of the 
washings. In patients with bronchoscopy without a diagnosis in the conventional 
procedure, the combined added diagnostic value of KRAS mutations and RASSF1 
methylation was 29%.  
Detailed clinical information about the 17 patients with nondiagnostic 
bronchoscopies is presented in Table 4. RASSF1A methylation was found in 4 of 
the 17 patients.  The mean tumor size in all patients was 3.3 cm (range, 1.5–
7.0 cm). Mean tumor size in the patients with methylated samples was 4.6 cm 
(range, 3–7 cm), compared with a mean tumor size of 2.9 cm (range, 1.5–4.5 
cm) in patients in which hypermethylation was not detected (p = 0.04). The KRAS 
mutations were present in larger tumors (4.0 and 4.5 cm) and patients were 
staged T2N0M0. RASSF1A methylation was present in 1 current smoker, 2 former 
smokers (> 20 pack years) and 1 never smoker, and KRAS mutations were present 
in current smokers. In 1 out of 17 patients, both RASSF1A methylation and KRAS 
mutations were found.  
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Table 4. Clinicopathologic variables for RASSF1A- and KRAS positive cases in those 
with negative conventional diagnostic bronchoscopy (n=17) 
SCC = squamous cell carcinoma; AC = adenocarcinoma; BAC = bronchioloalveolar 
carcinoma; LCC = large cell carcinoma
Thirteen controls were current smokers, 9 were former smokers (range: 8-40 
pack years), 2 never smoked and smoking information was missing in 4 controls. 
RASSF1A methylation was found in 1 control with a low methylation ratio (0.3), a 
smoking woman who was diagnosed with empyema with Streptococcus milleri. 
The KRAS mutation analysis of the washings was compared with the KRAS mutation 
analysis of the tumor biopsy specimens or resection samples. In the washing of 1 
patient, the same mutation was detected as in the tumor. In the other patient, a 
KRAS mutation was found in the washing but not in the biopsy. In a third patient 
with KRAS mutation in the tumor, the mutation was not found in the washing.  
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Discussion
This study shows that the detection of two biomarkers in endoscopic nonvisible 
lung cancer without a pathology diagnosis by bronchoscopy may better guide 
diagnostic procedures in patients with suspected lung cancer.
The rate of RASSF1A methylation found in our prospective collected series of 129 
bronchial washings is in agreement with other studies (Table 5).11,12,14,21,22 The 
significantly higher proportion of RASSF1a methylation in central tumors compared 
with peripheral tumors has been confirmed in our study. Not surprisingly, in other 
studies in which centrally located, endoscopic visible and larger tumors were also 
examined, a pathologic diagnosis by bronchoscopy is frequently obtained with 
concomitant increased detection of molecular alterations.9,14,22 In our study a 
larger tumor size was found in patients with methylated samples, suggesting that 
more methylated DNA or tumor cells are shed from larger tumors. 
Table 5. Overview of studies regarding analysis of RASSF1A hypermethylation in 
bronchial washings of lung cancer patients. 
Fraction methylated refers to the number of tumors showing DNA methylation; 
NSCLC = non-small cell lung cancer; SCLC = small cell lung cancer; (Q)MSP = (quantitative) 
methylation sensitive PCR
* three-marker methylation panel
Furthermore, in the subset of 17 patients with peripheral tumors in our study 
without diagnosis by bronchoscopy, RASSF1a methylation was present in 24%. In 
contrast to our study, most cases in other studies were diagnosed with carcinoma 
in the washings. To our knowledge, the number of studies examining RASSF1a 
methylation in peripheral tumors and a nondiagnostic bronchoscopy is small. 
Grote and colleagues detected RASSF1A methylation in 1 out of 4 lung cancer 
patients, a patient with SCLC, with nondiagnostic bronchoscopy.22 Schmiemann 
found methylation of a three-marker panel (among others of RASSF1A) in 9 of 26 
patients with peripheral tumors with a nondiagnostic bronchoscopy.14 In other 
studies, the tumor locations or the number of nondiagnostic bronchoscopies was 
not mentioned.11,12,21 
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A question arises as to whether the presence of RASSF1A methylation in washings 
is always due to the presence of lung cancer. Previous lung cancer studies 
comparing RASSF1A methylation in tumor tissues and bronchial washings showed 
a high concordance, indicating that methylation in these washings originated 
from the tumors.11,12,21 Accordingly, RASSF1A methylation was found 21% to 50% 
of sputum samples of lung cancer patients.26,30 
Earlier studies showed that RASSF1A methylation can appear months or years 
before clinical manifestations of lung cancer.31,32 Methylation may also arise 
in damaged epithelium as a result of smoking. In approximately 6% of heavy 
smokers, RASSF1A methylation was found, but the methylation ratio was not 
mentioned.33,34 The amount of RASSF1A hypermethylation in patients with lung 
cancer is much higher than the low proportion of methylation in controls. This 
difference may allow a threshold level to be set. In our study, one patient with 
empyema showed methylation with a methylation ratio below the cutoff value, as 
described by Shivapurkar et al.27 Other studies showed methylation levels of 0% 
to 4% in controls (Table 5). Only Topaloglu showed more frequent methylation in 
control samples (3/10), but the study also showed very low levels of methylation. 
The methylation yield in BAL could be higher due to the localized harvesting of 
tumor cells compared with bronchial washings. However, other studies showed 
that methylation can well be detected in washings with 10 to 30 ml of saline and 
even be found in cytologic nondiagnostic samples, as shown in our study.10,11,13,14 
Bronchial washing is a routine procedure for cytologic examination, whereas BAL, 
usually performed with 240 ml saline, is an extended bronchoscopic technique 
that prolongs the  duration of the procedure, carrying a small additional risk to 
the patient.35
In our study, the additional value of KRAS mutation analysis in the washings 
was limited. This result is in agreement with other studies in which KRAS 
mutations were present in 8% to 25% in the bronchial washings of nondiagnostic 
bronchoscopies.23-25 In contrast to the focus of our study, in these studies, 
endoscopic visible tumors were also examined, and tumor cells were found 
in brush specimens or biopsies with concomitant increased detection of KRAS 
mutations. This finding was not confirmed in our study, where the proportion of 
KRAS mutations in the washings did not differ between central and peripheral 
tumors. This result is probably due to the low frequency of adenocarcinoma in 
central tumors and the presence of KRAS mutations, mainly in adenocarcinomas. 
Because it is known that KRAS mutations appear in tumor cells and not in healthy 
subjects, the presence of KRAS mutations indicate an increased  probability of 
cancer cells. By combining analyses of KRAS mutations and RASSF1A methylation, 
29% of the false negative or doubtful cytology was correctly diagnosed as cancer. 
It cannot be excluded that the addition of other methylation markers may further 
enhance the accuracy of bronchoscopy. Although these biomarkers may better 
guide the diagnostic procedures of patients with suspected lung cancer, the final 
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diagnosis must be confirmed with histologic classification. Selecting patients by 
histology enables us to apply newer chemotherapy regimens and give personalized 
treatment. For instance, there is an association between the presence of KRAS 
mutations and a lack of response to EGFR tyrosine kinase inhibitors.36
Conclusion
Our data suggest that the detection of RASSF1A methylation in bronchial 
washings provides important evidence to suggest malignancy in a nondiagnostic 
bronchoscopy in patients suspected of NSCLC. Quantitative analysis of RASSF1A 
methylation in combination with KRAS in bronchial washing specimens is a 
promising diagnostic adjunct in the analysis of lung cancer. 
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Abstract
Introduction: Free DNA is present in serum of cancer patients in a higher 
concentration than non-cancer patients. Free DNA in sputum may originate 
from malignant or inflammatory diseases. The aim of the study was to examine 
the presence of free DNA in sputum and the relationship to lung cancer. The 
contribution of inflammatory cells was established as well. 
Patients and methods: The amount of free and cellular DNA in sputum was 
determined using real-time ß-globin PCR in 28 lung cancer patients and 68 
controls. 
Results: Free DNA was present in sputum samples of the cancer patients and 
controls. We found no differences in DNA concentration in sputum of patients 
with and without lung cancer. For all patients combined the amount of free 
DNA was related to the amount of inflammation. Further, we found increased 
hypermethylation of RASSF1A in lung cancer patients compared with controls to 
show that tumor related DNA is present in sputum. 
Conclusion: Free DNA can be detected in sputum of lung cancer patients.  The 
amount of free DNA is related to the amount of inflammation, but not to the 
presence of lung cancer. 
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Introduction
Lung cancer is the leading cause of cancer mortality worldwide.1 Despite growing 
therapeutically options, overall survival is only 15%. If lung cancer could be 
detected earlier, treatment and prognosis might be improved. Sputum cytology 
does not play a role in early detection of lung cancer.2-5 The proportion of tumor 
cells occurring in sputum of lung cancer patients may vary, but is usually < 1%. 
The average diagnostic yield of sputum cytology is 66% (range 22-98%).6-8 The 
diagnostic yield increases with endoscopic visible (central) tumors, the number of 
sputum specimens collected per patient, a large and/or high stage tumor (tumors 
greater than 2.4 cm in diameter) and histology (more in squamous cell carcinomas 
than in adenocarcinomas).9-12 
Earlier studies have shown that free DNA fragments are present in a considerably 
higher concentration in serum of lung cancer patients than in serum of healthy 
individuals or patients with benign disease.13-17 Free DNA in serum is not tumor 
specific and can be derived from tumors of any organ. In sputum free DNA may 
originate from malignant cells of lung cancer or upper airway cancer and also 
from inflammatory cells.18
The aim of this study was to examine the presence of free DNA in sputum and 
its relationship to the presence of lung cancer. The contribution of inflammatory 
cells to the amount of free DNA in sputum was explored. Further, we examined if 
free DNA originated from cancer cells by determining RASSF1A hypermethylation.
Patients and methods
Patients and sputum samples
A total of 28 lung cancer patients and 68 controls took part in the study. The 
subjects were recruited from an outpatient pulmonary clinic in 2002 and 2003. 
Pulmonary function was presented according to the guidelines of the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD) (88 patients).19 Smoking 
history was presented as never, former and current smokers (90 patients). Former 
smokers had quit smoking for at least one year. The study was approved by the 
institutional review board and informed consent was obtained from all subjects.
Three day pooled spontaneous sputum samples (n=145) were collected at home 
in 20 ml of Fixcyt® (48% ethanol/ 13 mM polyethylene glycol 1500 MW).11,20 
Several samples were collected on a different time point and treated as duplicates. 
77 Patients provided one sputum sample, 19 patients provided 2 to 9 sputum 
samples. Upon arrival, the fixed sputa were dithiotreitol (DTT) treated, filtered 
and centrifuged.21 After DTT treatment the supernatant was transferred into 4 
micro centrifuge tubes and centrifuged at 20.000-x g for 5 minutes. One ml of this 
supernatant was transferred to a new micro centrifuge tube and stored at -80°C 
until use. All cell pellets were resuspended in 1.5 ml of FixCyt®. An aliquot of 
the cell pellet was used for preparation of cellular monolayers and Papanicolaou-
Chapter 6
82
stained. A Feulgen thionin staining was performed for demonstration of smeared 
DNA.22 Specimens were considered to be adequate if alveolar macrophages and 
bronchial epithelial cells were present.5 The remaining material was stored at 
-20°C Tumor cells, inflammatory cells, free DNA and RASSF1A hypermethylation 
were determined in the sputum samples. 
Cytology preparation and examination
The slides with cellular monolayers were screened for the presence of atypical 
cells. Squamous cells were classified in normal cells, mild, moderate and severe 
atypia, carcinoma in situ or invasive carcinoma.23,24 Invasive carcinoma was 
classified as squamous cell carcinoma, adenocarcinoma, large cell carcinoma or 
small cell carcinoma according to the World Health Organization.23,24 In addition, 
the amount of inflammatory cells (143 samples) was divided in 4 categories: 
samples without inflammatory cells (0), 1-25% (1), 25-50% (2) and >50% 
neutrophilic granulocytes (3). 
DNA analysis
Sputum cell pellets were resuspended in phosphate-buffered saline (PBS) 
and DNA isolation was performed with spin columns (QIAamp DNA Blood 
Maxi kit, Qiagen) according to the “Blood and Body Fluid Spin Protocol” of the 
manufacturer. Sputum supernatant (1 ml) was used without the addition of PBS 
but with increased amounts of QIAGEN kit components proportionally. The same 
DNA isolation protocol was used for supernatant as for cells. DNA was eluted 
with 100 μl buffer and 10 μl was used for the quantification of human DNA using 
a real-time beta-globin polymerase chain reaction (PCR) method targeting a 71 
bp fragment within exon 3 of the human ß-globin gene.25 All quantitations were 
performed in triplicate and mean DNA was expressed as the amount of DNA in ng 
per 1 ml of sputum/Fixcyt solution. 
We investigated RASSF1A hypermethylation as marker of tumor related DNA.26 
In our hands RASSF1A is more frequently present in sputum of lung cancer 
patients than in controls (data not shown). RASSF1A hypermethylation analysis 
was performed as described previously.27,28 A part of the samples could not be 
analyzed because of limited remaining DNA quantities (19 lung cancer samples 
and 37 control samples). Both first and second step PCR reaction comprised of 30 
cycles. The amount of modified DNA used in the first PCR step was up to 400 ng 
for the DNA that originated from sputum cell pellets and 0.04 to 319 ng for DNA 
from sputum supernatants (the maximal amount of the DNA material available). 
All assays were at least performed in duplicate. When two results were the same, 
the outcome was considered to be conclusive. In case of an inconclusive outcome 
a third assay was done, which was decisive for the outcome. 
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Statistical analysis 
For free and cellular DNA the mean and standard error (SE) were determined. For 
statistical comparison a nonparametric Mann-Whitney U or Kruskal-Wallis H was 
used. Frequencies of hypermethylation of RASSF1A in the sputum samples were 
compared with a chi-square test. A p-value of < 0.05 was regarded as significant. 
Data were analyzed with SPSS/PC+, version 12.0 (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
The mean age (range) of cancer patients and controls did not differ significantly 
(68 years (range 46-88) and 66 years (range 40-87), respectively; p = 0.36). In 
cancer patients there were significantly more women compared with controls (p < 
0.001) (Table 1). Mean forced expiratory volume in one second (FEV1) (range) did 
not differ significantly between cancer patients and controls (1.83 L (0.82–3.67) 
and 1.73 L (0.60–3.68) respectively, p = 0.55). 26 of the 28 lung cancer patients 
had chronic obstructive pulmonary disease (COPD) (GOLD stages: I: 11 (42.3%); II: 
9 (34.6%); III: 6 (23%)). 57 of the 68 controls had COPD (GOLD stages: I: 18 (29%); 
II: 19 (30.6%); III: 17 (27.4%); IV: 3 (4.8%)). Five controls (8.2%) did not have COPD. 
In 2 lung cancer patients and 6 controls GOLD stages were unknown. In cancer 
patients there were significantly more former smokers than in controls (p < 0.001) 
and in controls were significantly more current smokers (p < 0.001). In 1 lung 
cancer patient and 5 controls smoking history was unknown.
Cytologic examination
The cytologic examination of the sputum samples of the lung cancer patients 
and controls is presented in Table 2. Most sputum samples of controls showed 
no abnormalities (93.8%). Malignant cells were present in sputum of 16 lung 
cancer patients  (57%). In Table 3 histologic subtypes and tumor stage according 
to the revised lung cancer staging system are presented, 46% had squamous 
cell carcinoma.29 Tumor stage of 4 patients was unknown. At bronchoscopy 11 
patients had an endoscopic visible (central) tumor, 14 patients had an endoscopic 
nonvisible (peripheral) tumor, 1 patient did not have a bronchoscopy and 
information of 2 patients was not available.
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Table 1. DNA concentration in sputum of lung cancer patients (n=28) and controls 
(n=68).
*: p < 0.001 versus cellular DNA 
Table 2. Sputum DNA according to cytologic analysis. 
Data are presented for sputum samples of lung cancer patients (n=49) and controls (n=96). 
CIS: carcinoma in situ; NT = not tested
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Table 3. Sputum DNA of lung cancer patients (n=28) according to tumor 
characteristics. 
SCLC-LD: small cell lung carcinoma-limited disease; SCLC-ED: small cell lung carcinoma-
extensive disease. P-values: comparisons among subdivisions
DNA analysis
The mean concentration of free DNA was significantly lower than the mean 
concentration of cellular DNA in lung cancer patients (p < 0.001) and controls 
(p < 0.001; Table 1). No differences in free and cellular DNA concentration were 
found in sputum between patients with and without lung cancer (p = 0.30 and 
p = 0.10, respectively). Sex, age and smoking status did not correlate with the 
free or cellular DNA concentration in both lung cancer patients and controls. In 
cancer patients, GOLD stage did not influence mean free or cellular DNA (p = 0.42 
and p = 0.60, respectively). In controls, mean free DNA was significantly higher in 
patients with higher GOLD stage (p = 0.01), but mean cellular DNA did not differ 
significantly between GOLD stages (p = 0.66).
The presence of malignant cells in the sputum samples of lung cancer patients 
was not related to the concentration of free DNA (p = 0.66) or DNA in the cellular 
fraction (p = 0.66) (Table 2). The samples with atypical / malignant cells were 
evenly distributed over the four inflammatory categories. In cancer patients mean 
free and cellular DNA did not differ significantly among histologic subtypes (p = 
0.24 for free and p = 0.30 for cellular DNA), tumor stage (p = 0.33 and p = 0.82, 
respectively) (Table 3) or centrally or peripherally  located tumors at bronchoscopy 
(p = 0.19 and p = 0.44, respectively).
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The concentration of free and cellular DNA in the four inflammatory categories is 
shown in Table 4. Free DNA was present in all sputum samples of cancer patients 
and controls. For all patients combined the amount of free and cellular DNA was 
related to the amount of inflammation (p = 0.01 and p < 0.001, respectively). 
The free DNA concentration in sputum of lung cancer patients was significantly 
increased in the subgroup with more than 50% neutrophilic granulocytes 
compared with the samples with 1-25% neutrophilic granulocytes (p = 0.006). The 
free DNA concentration in controls was significantly increased in the subgroup 
with more than 50% of neutrophilic granulocytes compared with the samples with 
25-50% neutrophilic granulocytes (p = 0.03). The cellular DNA concentration in 
lung cancer patients was similar in the subgroups of inflammation (p = 0.26). The 
cellular DNA concentration in controls was significantly increased in the subgroup 
with more than 50% of neutrophilic granulocytes compared with samples with 
less than 50% (p ≤ 0.001). Smoking did not influence the amount of inflammation 
in both cancer patients and controls (p = 0.15 and p = 0.11, respectively).
Table 4. Sputum DNA of lung cancer patients (n=48) and controls (n=95) according 
to the inflammatory categories.
*: p = 0.006 versus 1–25% neutrophilic granulocytes; ¶: p = 0.03 versus 25–50% neutrophilic 
granulocytes; #: p = 0.002 versus 0% neutrophilic granulocytes and p < 0.001 versus 1–25% 
and  25-50% neutrophilic granulocytes
RASSF1A analysis 
The result of the RASSF1A analysis is shown in Table 5. Hypermethylation of 
RASSF1A of both free and cellular DNA was significantly increased in lung cancer 
patients compared with controls (p < 0.001). In free DNA methylation of RASSF1A 
was present in 20% of the lung cancer patients and not in controls. In cellular DNA 
methylation of RASSF1A was present in 42.9% of the lung cancer patients and in 
1.4% of the controls. 
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Table 5. RASSF1A methylation analysis of sputum DNA of lung cancer patients 
(n=28) and controls (n=68).
Data are presented in numbers. *: p < 0.001 versus controls
Discussion
In this study, we demonstrated the presence of free DNA in all sputum samples. 
No differences were found in free DNA concentration in sputum of lung cancer 
patients compared with controls. However, we found that the amount of free 
DNA was related to the amount of inflammatory cells.
The average diagnostic yield of sputum cytology is approximately 66%.6-8 In our 
study with 3-day pooled samples the diagnostic yield was comparable (57%). The 
present study was performed to investigate if free DNA can be detected in sputum 
and its relationship to lung cancer. To the best of our knowledge there are no 
previous data on free DNA in sputum and the relation to lung cancer. Theoretically, 
free DNA may be present in the epithelial lining fluid. Free DNA may be derived 
from all airway epithelial cells underneath the lining fluid, from the alveolar 
macrophages and disease related cells such as inflammatory cells and tumor cells. 
Because tumor cells comprise only a minor fraction in most sputum samples, the 
amount of tumor DNA in sputum is likely to be low. In our study the concentration 
of free DNA was 10 fold lower compared with the concentration of cellular DNA. 
No significant differences were found in both free and cellular DNA concentration 
in sputum of patients with lung cancer compared with controls. In this study we 
performed hypermethylation of RASSF1A to show that tumor related DNA is 
present in sputum. Hypermethylation for RASSF1A was present in 13 lung cancer 
patients (46.4%) in contrast to hypermethylation in 1 control (1.4%). Honorio et 
al. also found that hypermethylation of RASSF1A was detectable in sputum in 
about 21% NSCLC and in 50% small cell lung cancer (SCLC) sputum samples.30 Our 
finding of significant increased RASSF1A hypermethylation in sputum in a small 
number of lung cancer patients is interesting to explore in a further study in a 
larger group of patients.
It is likely that the majority of degenerating tumor cells in sputum originate from 
the lung tumors that are endobronchial visible at bronchoscopy. However, about 
38% of the lung tumors are not visible at bronchoscopy.31 In addition the possibly 
shredded tumor cells have to be transported together with the mucus on the 
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surface of the proximal airways and coughed up. In the present study mean free 
and cellular DNA in lung cancer patients did not differ significantly among centrally 
or peripherally located tumors at bronchoscopy. 
In an inflammatory disease such as COPD, with or without acute component, the 
epithelial lining fluid increases in volume due to increased mucus production, 
increased permeability of the respiratory mucosa, the presence of inflammatory 
cells and secreted anti-inflammatory components.7,32 Lytic inflammatory cells 
may contribute to the free DNA fraction. We found that free DNA was present in 
all sputum samples of both the lung cancer patients and controls regardless the 
amount of inflammation, thus also in those samples without inflammation. Most 
lung cancer patients are ex- or current smokers and about 50% have COPD.33 In 
our study 93% of lung cancer patients had COPD. In addition it appeared that the 
amount of free DNA increases proportionally with the amount of inflammatory 
cells. This is in line with the findings of Gautschi and coworkers, who observed a 
strong correlation between neutrophils and free DNA in serum of NSCLC patients.18 
The increased amount of free DNA due to neutrophilic granulocytes was so large 
that a possible minor increase of free DNA due to a malignant process was not 
likely to be detected. In controls, mean free DNA was significantly higher in 
patients with higher GOLD stage. Probably this is related to the increased amount 
of neutrophilic granulocytes in sputum.34 Although in cancer patients there were 
more former smokers and in controls there were more current smokers, smoking 
status did not correlate with free or cellular DNA concentration in both lung 
cancer patients and controls.  
Conclusion
The results of the present study show that free DNA can be detected in sputum 
of lung cancer patients and controls. The amount of free and cellular DNA was 
related to the amount of inflammatory cells present as a result of COPD, but not 
to the presence of cancer. 
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Circulating DNA is a non-invasive prognostic factor 
for survival in non-small cell lung cancer
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Abstract
Introduction: Circulating plasma DNA is present in a considerably higher 
concentration in lung cancer patients than in controls. Conflicting data are 
reported about circulating DNA as a prognostic factor. The aim of this study was 
to prospectively analyse the relationship of circulating plasma DNA with overall 
survival (OS) of previously untreated non-small cell lung cancer (NSCLC) patients.
Patients and methods: 46 untreated NSCLC patients and 21 controls with a follow-
up time of 6.5 years were analysed. Quantification of baseline circulating plasma 
DNA was performed by a real-time quantitative polymerase chain reaction (qPCR) 
targeting the human ß-globin gene. Survival analysis was performed using the 
Kaplan-Meier method and compared with a Cox-regression analysis.
Results: The median DNA concentration of the patients who died (87%) was 
significantly higher compared with the patients that survived at the end of 
follow-up (55 ng/ml versus 23 ng/ml, p = 0.02). In patients with higher DNA 
concentration overall survival was significantly worse. In this study no relation 
of DNA concentration with tumor characteristics, age, gender or pulmonary 
inflammatory conditions was found. 
Conclusion: In this study a high circulating plasma DNA concentration at time of 
diagnosis in NSCLC patients was a prognostic factor for poorer survival. Circulating 
DNA may be used as a non-invasive biomarker to refine the prognostic profile in 
NSCLC patients. 
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Introduction 
Lung cancer is the leading cause of death by cancer worldwide. At the time of 
diagnosis, lung cancer is often locally or systemically advanced and overall survival 
is 15%.1 Prognostic factors predict survival independent of the treatment applied 
and can classify patients as high or low risk. The most important prognostic factor 
is stage according to the TNM system.2,3 Other prognostic factors include clinical 
aspects (e.g. gender, age, weight loss, cardiovascular disease), elevated lactate 
dehydrogenase levels4-6, FDG-PET scan7 and pathological aspects.8-10 Increasingly, 
multiple genetic and epigenetic alterations are under investigation as prognostic 
factors for survival.11-14 
Since many years free or circulating DNA in plasma or serum of (lung) cancer 
patients is under investigation for clinical relevance. Circulating plasma DNA is 
present in considerably higher concentrations in lung cancer patients compared 
with healthy controls or patients with benign disease.15-19 The increased circulating 
DNA concentration is thought to originate from cancer cells.20-22 Conflicting data 
have been reported about circulating DNA as a prognostic factor in lung cancer 
patients. Some studies showed a correlation between an elevated plasma DNA 
concentration and poor survival23,24, whereas other studies did not report a such 
a relationship.25-27 This might be explained by differences in patient selection, 
covering both non-small cell lung cancer (NSCLC) and small cell lung cancer 
(SCLC), and both treated and untreated patients. Besides, techniques for sample 
collection and DNA quantification differed between these studies. Thus, at present, 
the prognostic value of circulating DNA for survival has not been established yet. 
Also the relationship of circulating DNA with age, gender, histology, stage and 
pulmonary inflammatory conditions is not clear. 
The aim of our study was to analyse if elevated circulating DNA is a prognostic 
factor for survival in NSCLC patients. The present study reports 46 untreated 
NSCLC patients and 21 controls with a follow-up time of 6.5 years. A real-time 
quantitative polymerase chain reaction (qPCR), the current standard method to 
quantitate DNA, was applied to determine the baseline plasma DNA concentration 
at the time of diagnosis. 
Patients and methods
Study design
In the Canisius-Wilhelmina hospital, Nijmegen, 77 consecutive patients suspected 
of having lung cancer by signs, symptoms or chest X-ray were prospectively 
recruited between June 2001 and September 2003. Patients in whom no lung 
cancer was diagnosed served as controls; none of them developed lung cancer 
during follow-up. 10 Patients with SCLC were excluded. Overall survival (OS) 
was computed from the date of diagnosis to the date of death or the date of 
last follow-up. Survival data were obtained until January 2009. Smoking history 
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was presented as current, former and never smokers. Former smokers had quit 
smoking for at least one year. Information about smoking of 1 control patient 
was missing. Pulmonary function was presented as classification of chronic 
obstructive pulmonary disease (COPD) according to the guidelines of the Global 
Initiative for Chronic Obstructive Lung Disease (GOLD).28 The study was approved 
by the institutional review board and informed consent was obtained from all 
participants. 
Sample collection, DNA isolation and quantification
A 10 ml sample of peripheral blood was collected in EDTA tubes from patients 
before surgery, chemo- or radiotherapy and from controls. Within 1 h after 
collection, EDTA-blood samples were subjected to two centrifugation steps. 
After initial centrifugation of the original tube for 10 min at 2,000 x g at 20°C, the 
supernatants were transferred to micro centrifuge tubes and centrifuged again 
for 5 min at 16,000 x g at 20°C. Subsequently, the supernatant was stored at –20°C 
before analysing the DNA content.
DNA was isolated from 1 ml of plasma using the MagNA Pure LC Total Nucleic Acid 
Isolation Kit - Large Volume (Roche diagnostics) and eluted in 100 µl of elution 
buffer. The DNA concentration was measured by using a previously described 
highly reproducible real-time quantitative polymerase chain reaction (qPCR) 
targeting the human ß-globin gene.29 Primer and probe sequences were used 
as described. The qPCR was performed on a LightCycler 1.2 instrument (Roche 
diagnostics) in a final volume of 20 µl containing 0.25 µM of amplification primers, 
0.1 µM detection probe and 3 mM MgCl2 (total concentration) in 1x LightCycler 
FastStart DNA Master HybProbe (Roche Diagnostics). A calibration curve was 
made from pure human lymphocyte DNA that was quantified by UV absorbance 
measurements. The qPCR program consisted of an initial denaturation of 10 min 
at 94°C followed by 40 cycles of 0 s at 95° and 15 s at 60°C with maximal ramping 
rates. Data were analyzed using the second derivative maximum method. DNA 
was expressed in ng per ml of plasma. Mean storage of DNA samples before 
analysis was 12.2 (range 5.4 – 20) months for NSCLC patients and 11.2 (range 5.2 
– 14.5) months for controls. Storage time did not influence DNA concentration 
(data not shown).
Statistical analysis
Data were analyzed with SPSS/PC+, version 16.0 (SPSS, Inc., Chicago, IL). 
Descriptive statistics were used for clinical characteristics and comparisons were 
performed by t-tests or Chi-square tests, as appropriate. Differences in DNA 
concentrations between NCSLC patients and controls were analyzed using a 
nonparametric Mann-Whitney U or Kruskal-Wallis test, as appropriate. Survival 
analysis, according to three tertiles of DNA distribution, was performed using the 
Kaplan-Meier method and compared with a Cox-regression analysis according to 
Sozzi et al.30 For the diagnostic discrimination of DNA concentrations between 
95
Circulating DNA related to NSCLC prognosis
7
cancer patients and controls the area under the curve of the receiver operating 
characteristic curve (AUC-ROC) was assessed non-parametrically. A p-value of 
≤ 0.05 was regarded as significant.
Results
Baseline characteristics
46 NSCLC patients and 21 controls were analysed. Patient characteristics are 
summarized in Table 1. In the patient group there were significant less males than 
in the control group (65% and 90%, respectively; p = 0.04). Smoking history was 
equally divided between patients and controls (p = 0.85). 30 Patients (65%) and 
11 controls (52%) had COPD. The mean forced expiratory volume in one second 
(FEV1) percentage predicted did not differ between patients and controls (p = 
0.06) and GOLD stages were divided equally between both groups (p = 0.54).
In patients, the median DNA concentration was significantly higher than in controls 
(52 ng/ml (range 5-3597) and 29 ng/ml (range 0-175), respectively; p = 0.03). 
Table 1. Clinical characteristics of non-small cell lung cancer (NSCLC) patients (n = 
46) and controls (n = 21). 
FEV1 = mean forced expiratory volume in one second; COPD = chronic obstructive 
pulmonary disease; GOLD = Global Initiative for Chronic Obstructive Lung Disease
Follow-up and relationship to DNA concentration
Maximum follow-up time was 6.5 years. At the date of last follow-up 40 patients 
(87%) and 2 controls (9.5%) had died. 12 patients staged I-III relapsed after therapy 
or developed metastases (41.4%) after median 15 months (range 1.5-51.5). 
Median OS was significantly decreased for patients compared with controls (13.7 
months (range 1.1-78.4) and 67.6 months (range 2.0–78.2), respectively; p < 
0.001). The median DNA concentration of the patients who died (n = 40) was 
significantly higher compared with the patients that survived (n = 6) at the end of 
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follow-up (55 ng/ml versus 23 ng/ml, p=0.02). Survival analysis, using the Kaplan-
Meier method and compared with a Cox-regression analysis, was performed 
according to three tertiles of DNA distribution (Table 2). In patients with DNA 
concentration in the middle and upper tertiles (≥ 32 ng/ml) overall survival was 
significantly shortened (Figure 1).
The AUC-ROC for discrimination of DNA concentrations between patients and 
controls was 0.66 (95% confidence interval 0.53 to 0.80, p = 0.03). A DNA cut-off 
level of > 32 ng/ml differentiated between lung cancer patients and controls with 
a specificity of  52% and sensitivity of 67%. 
Table 2. Survival analysis in non-small cell lung cancer (NSCLC) patients according 
to three tertiles of DNA distribution. 
HR = hazard ratio; *p = 0.04 versus tertile 1; **p = 0.03 versus tertile 1
Figure 1. Overall survival and correlation to circulating DNA in plasma of lung 
cancer patients.
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Clinical characteristics and relationship to DNA concentration
Table 3 summarizes the DNA concentration according to the clinical and tumor 
characteristics. Median DNA concentration differed neither between men and 
women in patients (p = 0.71) nor in controls (p = 0.91). Age was not related to 
DNA concentration in patients (p = 0.25) nor in controls (p = 0.43). Smoking was 
not related to DNA concentration in patients (p = 0.85), but in controls DNA 
concentration was significantly increased in former smokers compared with 
current smokers (p = 0.02). GOLD stages were not related to DNA concentration 
in patients (p = 0.83) nor in controls (p = 0.88).
(Locally) advanced disease was observed in 58.7% of the patients. In patients no 
relation was observed between DNA concentration and histology (p = 0.35) or 
tumor stage (p = 0.39). 3 Controls developed cancer during follow-up (metastasized 
colon carcinoma, mamma carcinoma and renal cell carcinoma) with DNA levels 
ranging 6-26 ng/ml.
Table 3. Median DNA concentration (ng/ml) according to clinical and tumor 
characteristics of the non-small cell lung cancer (NSCLC) patients (n=46) versus 
controls (n=21). 
IQ = interquartile; SCC = squamous cell carcinoma; AC = adenocarcinoma; LCC = large cell 
carcinoma; disease; IQ = interquartile
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Discussion
The aim of this study was to analyse circulating plasma DNA as a prognostic 
factor for survival of NSCLC patients at time of diagnosis. The results show that 
a high circulating DNA concentration correlates with poor survival. We did not 
find a relationship of DNA concentration with clinical parameters as age, gender, 
histology, stage, smoking or pulmonary inflammatory conditions.
Since many years circulating DNA in plasma of lung cancer patients is under 
investigation as a promising non-invasive diagnostic or prognostic biomarker. 
The source of DNA circulating in plasma is uncertain. It is presumed that 
circulating DNA in healthy subjects or patients with benign disease is derived 
from lymphocytes, leucocytes or other damaged inflammatory cells. In cancer 
patients a considerable part of circulating plasma DNA is derived from cancer 
cells as is shown by the presence of specific oncogene or tumor-suppressor gene 
mutations, hypermethylation of several genes or other (epi)genetic changes.22,31 
Several mechanisms of DNA release have been proposed such as apoptosis or 
lysis of cancer cells and leakage in the blood stream.18,21,23,32
Table 4. Overview of studies regarding analysis of circulating DNA in plasma/
serum of lung cancer patients as a prognostic factor. 
NSCLC = non-small cell lung cancer; qPCR = real-time polymerase chain reaction; G-3-
PD = glyceraldehyde-3-phosphate dehydrogenase; hTERT = human telomerase reverse 
transcription
For the quantification of DNA, we selected a real-time PCR assay designed for 
the ß-globin sequence that performed consistently in other experiments.29,33 Real-
time PCR for DNA quantification can be regarded as the standard method.34 PCR 
based technology was introduced in the late 1980s and refinements in the last 
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decade resulted in the quantification of extremely small amounts of nucleic acids. 
Different genes can be used for amplification, depending on the experience of the 
institute. 
In our study, the median DNA concentration in lung cancer patients was significantly 
higher compared with controls, which is in agreement with former studies.15-19 
The AUC-ROC for discrimination of DNA concentrations between patients and 
controls was 0.66, which is comparable with AUC levels in other studies.35-37 
The DNA concentration of the patients who had died during follow-up was 
significantly higher compared with those patients that survived at the end of this 
period. Survival analysis, according to three tertiles of DNA distribution, showed a 
significantly worse survival in patients with DNA concentration in the middle and 
upper tertiles. Several studies did not show a correlation of DNA concentration to 
survival25-27, whereas others showed that a higher DNA concentration did correlate 
to poorer survival.23,24 In a recently published lung cancer screening study, 
survival was also worse in patients with plasma DNA concentration in the upper 
tertile.30 According to the 3 tertiles in our study, we found a virtual cut-off level 
of 32 ng/ml, but the sensitivity and specificity were disappointing (67% and 52%, 
respectively). Sensitivity and specificity estimates for different DNA cut-off values 
were also computed and as to be expected higher cut-off levels went together 
with increased specificity but lower sensitivity and vice versa. In previous studies 
DNA cut-off levels ranged from 3.25 to 100 ng/ml and were dependant of the 
assays and genes used to isolate circulating DNA (Table 4).15,16,35-40 Nevertheless, 
the cut-off level in our study is not at variance with most of these studies.35-38 As 
the DNA concentration consists of continuous variables, dividing DNA according 
to tertiles seems to have a stronger clinical value than determining cut-off levels 
with an ample variety of sensitivity and specificity. 
Possible explanations for the discrepancy in survival data are patient and sample 
selection. An overview of studies regarding analysis of circulating DNA in plasma 
or serum of lung cancer patients as a prognostic factor is presented in Table 4. 
In some studies both NSCLC and SCLC patients were combined.23,26 Since NSCLC 
and SCLC differ in biology, treatment and prognosis, only NSCLC patients were 
selected in our study. Some studies were performed with both newly diagnosed 
and relapsed NSCLC patients.16,24 It is not yet clear how DNA concentration is 
influenced by therapy. A lower DNA concentration was found after surgery 
compared with baseline DNA concentration.19,25,27 Those patients with an increase 
in DNA concentration after surgery showed recurrence of malignancy. On the 
other hand, Gautschi et al. did not find a decrease in DNA concentration after 
treatment with chemotherapy.24 To avoid an altered DNA concentration after 
treatment in our study, baseline DNA concentration of yet untreated lung cancer 
patients was determined. 
Another potential bias for differences in outcomes in similar survival studies is the 
method of DNA isolation. As discussed before, qPCR for DNA quantification can be 
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regarded as the standard method and can detect a large range of small amounts 
of nucleic acids. Other techniques have a detecting range with lower upper DNA 
levels, for instance a range of 0 - 1000 ng/ml for the radioimmunoassay and pico 
green quantification16,41 or 0 - 2000 ng/ml for nick translation DNA labeling.23 In 
our study DNA values up to 3597 ng/ml were detected. The possible significance 
of higher DNA values might have been missed in studies with older assays. 
There is some doubt about the quality of DNA after prolonged storage. In a brief 
report Sozzi showed that DNA levels declined at about 30% per year.42 In our study 
mean storage of DNA samples before analysis was one year. When analysing 
DNA at different time points of storage between 6 months and one year, DNA 
concentration did not differ significantly. This latter observation was also reported 
by Frattini.43
DNA concentration in our study was not influenced by tumor characteristics, 
age, gender and conditions associated with inflammation. Our results show that 
neither histological subtypes nor stage in NSCLC patients were related to DNA 
concentration which is in agreement with previous studies.19,25,26,44 The studies 
that reported higher DNA concentration in advanced NSCLC were performed 
in a selected group of patients of whom a substantial part had received prior 
treatment.16,24 As discussed before, DNA concentration might be influenced by 
treatment. The mean age of cancer patients was significantly higher than the 
mean age of controls in our study. The mean age of 66.7 years in lung cancer 
patients is in agreement with the appearance of lung cancer at higher age in the 
population. Age was not related to DNA concentration in lung cancer patients, 
which is in agreement with one19, but not another study by the same author.25 
Our results showed that gender and smoking in cancer patients were not related 
to DNA concentration which is in agreement with other studies. Unexpectedly, in 
control patients DNA concentration of former smokers was increased compared 
with current smokers. Possibly this is due to the small range of DNA concentration 
in controls compared with the larger range in cancer patients. 
As circulating plasma DNA is also higher in patients with benign disease, the 
relationship of DNA with pulmonary conditions associated with inflammation, 
such as COPD and smoking, was analysed. In our study 65% of the patients had 
COPD, compared with 50% in another study.45 In previous studies, the amount of 
circulating DNA increased proportionally with the amount of inflammatory cells in 
sputum and serum, but not in plasma.24,33 In these studies free DNA concentration 
was not related to GOLD stage, which is in line with the results of our study. 
In our study 3 controls developed cancer during follow-up and had low DNA 
levels. In a recently published lung cancer screening study, median baseline 
concentration of plasma DNA did not differ between individuals who developed 
lung cancer during follow-up versus cancer-free controls.30 
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Conclusion 
In this study a high circulating plasma DNA concentration at time of diagnosis 
was a prognostic factor for poorer survival of NSCLC patients. No relationship 
was found between DNA concentration and histology, stage, age, gender or 
inflammatory pulmonary conditions as COPD or smoking. Circulating DNA may 
be used as a non-invasive biomarker requiring only a blood sample to refine the 
prognostic profile in NSCLC patients.
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Abstract 
Introduction: The prognosis of small cell lung cancer (SCLC) is poor. Most 
prognostic factors are based on clinical characteristics and studies to (epi)genetic 
changes as prognostic factors are limited. Circulating plasma DNA, increased in 
cancer patients compared with controls, is an unfavorable prognostic biomarker 
in patients with non-small cell lung cancer (NSCLC). Little is known about the 
prognostic value of circulating DNA in SCLC. The aim of this study was to explore 
circulating DNA as a prognostic factor for survival in SCLC. 
Patients and methods: In 10 SCLC patients and 21 controls quantification of 
baseline circulating plasma DNA was performed by a real-time quantitative PCR 
targeting the human ß-globin gene. Survival analysis was performed using the 
Kaplan-Meier method and compared with a Cox-regression analysis. Follow-up 
time was 6.5 years.
Results: In SCLC patients, the median DNA concentration was significantly higher 
compared with controls (163 ng/ml and 29 ng/ml, respectively; p = 0.004). We 
found a correlation between higher plasma DNA concentration and poorer 
survival in SCLC patients (p = 0.04, HR 1.6). The median DNA concentration of 
the patients, who died within 10 months after diagnosis, was significantly higher 
compared with the patients, who died after 10 months (p =0.05). 
Conclusion: Our results suggest that circulating DNA should be evaluated as a 
potential prognostic biomarker in SCLC. 
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Introduction 
Lung cancer is the most fatal solid cancer in developed countries. Small cell 
lung cancer (SCLC) is an aggressive tumor and frequently metastasized at time 
of diagnosis. The prognosis of SCLC is poor despite multimodality therapy, even 
for limited disease. Most prognostic factors are based on clinical characteristics. 
Favourable clinical prognostic factors for survival of SCLC patients include younger 
age, female gender, former smoking, better performance status and limited 
disease.1 Studies to (epi)genetic changes, e.g. increased expression of proteins, as 
prognostic factors for survival in SCLC patients are limited.2,3 A small study in SCLC 
patients showed a better median survival in the presence of both microsatellite 
alterations and TP53 mutations in plasma.4
Increasingly, circulating tumor-derived DNA and RNA markers in blood are under 
investigation.2 Circulating plasma DNA is increased in patients with cancer or – to 
a lesser degree – benign disease.5 Most studies about circulating plasma DNA as a 
diagnostic or prognostic biomarker in lung cancer were performed in patients with 
non-small cell lung cancer (NSCLC). The unfavorable prognostic value of a high 
circulating plasma DNA concentration at time of NSCLC diagnosis was discussed 
in several studies.5-7 
In SCLC patients, only a few studies to circulating DNA were performed. They 
reported increased quantities of circulating DNA in SCLC patients at time of 
diagnosis compared with controls. However, the prognostic value of circulating 
DNA in these patients is not clear.8,9 In these studies initially developed non-
quantitative methods were used in a mixed population of NSCLC and SCLC patients. 
We performed an exploring analysis in a selected group of SCLC patients to 
investigate the potential role of circulating DNA as a prognostic factor for survival. 
A real-time quantitative polymerase chain reaction (qPCR), the current standard 
method to quantitate DNA, was applied to determine the baseline plasma DNA 
concentration at the time of diagnosis. 
Patients and methods
Patients
Patients referred for (suspected) lung cancer were prospectively recruited for 
circulating DNA analysis and selected for this study upon diagnosis of SCLC. The 
patients in whom no lung cancer was diagnosed served as controls.7 Overall 
survival was computed from the date of diagnosis to date of event occurrence or 
date of last follow-up until January 2009. Clinical characteristics including tumor 
characteristics and conditions associated with inflammation as smoking status 
and chronic obstructive lung disease (COPD) were registered. Pulmonary function 
was presented according to the guidelines of the Global Initiative for (Gold).10 The 
study was approved by the institutional review board and informed consent was 
obtained from all participants. 
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DNA extraction and quantification
A 10 ml baseline peripheral blood sample was collected in EDTA tubes and 
centrifugated in two steps within 1 h after collection. After initial centrifugation of 
the original tube for 10 min at 2,000 x g at 20°C, the supernatants were transferred 
to micro centrifuge tubes and centrifuged again for 5 min at 16,000 x g at 20°C. 
The supernatant was stored at –20°C before DNA analysis. DNA was isolated 
from 1 ml of plasma using the MagNA Pure LC Total Nucleic Acid Isolation Kit - 
Large Volume (Roche diagnostics) and eluted in 100 µl. The DNA concentration 
was determined by using a highly reproducible real-time quantitative polymerase 
chain reaction (qPCR) targeting the human ß-globin gene.7 The qPCR was 
performed on a LightCycler 1.2 instrument (Roche diagnostics) in a final volume of 
20 µl containing 0.25 µM of amplification primers, 0.1 µM detection probe and 3 
mM MgCl2 (total concentration) in 1x LightCycler FastStart DNA Master HybProbe 
(Roche Diagnostics). A calibration curve was made from pure human lymphocyte 
DNA that was quantitated by UV absorbance measurements. The PCR program 
consisted of an initial denaturation of 10 min at 94°C followed by 40 cycles of 0 
s at 95° and 15 s at 60°C with maximal ramping rates. Data were analyzed using 
the second derivative maximum method. DNA was expressed in ng/ml of plasma.
Statistics
Data were analysed with SPSS/PC+, version 16.0 (SPSS, Inc., Chicago, IL). 
Descriptive statistics were used for clinical characteristics and comparisons were 
performed by t-tests. Differences in DNA concentrations between patients and 
controls were analysed using a nonparametric Mann-Whitney U test. Differences 
in survival between patients and controls were compared with a log-rank test 
(Kaplan-Meier). A Cox regression model was used to assess the prognostic 
effect of DNA concentration on survival in SCLC patients. A p-value of ≤ 0.05 was 
regarded as significant. 
Results
Clinical characteristics
Characteristics of the 10 SCLC patients, 80% staged extensive disease, and 21 
controls are summarized in Table 1, including 87% males. The mean age of patients 
was just significantly higher than the mean age of controls (p = 0.05). 80% of the 
patients and 57% of the controls were current smokers. Former smokers had quit 
smoking for at least one year. Information about smoking of 1 control patient 
was missing. 3 Patients (30%) and 11 controls (52%) had COPD. The mean forced 
expiratory volume in 1 s (FEV1) in patients was just significantly lower compared 
with controls (p = 0.05). 
DNA concentration and clinical characteristics
In patients, the median DNA concentration was significantly higher compared 
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with controls (p = 0.004) (Table 2). The median DNA concentration was 2284 
ng/ml in patients with limited disease (n=2) and 163 ng/ml (IQ range 3517) in 
patients with extensive disease (n=8). Comparison of median DNA concentration 
in SCLC patients and controls according to clinical and tumor characteristics was 
not calculated due to small patient numbers. 
Table 1. Clinical characteristics of small cell lung cancer (SCLC) patients (n = 10) 
and controls (n = 21). 
Data are presented as number of patients, except for age and FEV1 (= mean forced 
expiratory volume in 1 s). COPD = chronic obstructive pulmonary disease; GOLD = Global 
Initiative for Chronic Obstructive Lung Disease
Table 2. Median DNA concentration (ng/ml) according to clinical and tumor 
characteristics of the small cell lung cancer (SCLC) patients (n=10) and controls 
(n=21).
IQ = interquartile; *p-value = 0.004 versus controls
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Relationship of DNA concentration to survival
At the date of last follow-up all SCLC patients and 2 controls (9.5%) had died. 
None of the control patients developed lung cancer or any other solid tumor 
during a follow-up period of median 67.6 months (range 3-78). Survival analysis 
is presented in Table 3. Mean overall survival was significantly decreased for 
patients compared with controls, as expected. A higher DNA concentration was 
related to worse survival (p = 0.04, HR 1.6). The median DNA concentration of the 
patients that died within 10 months after diagnosis (n=6) was higher compared 
with the patients that died after 10 months (n=4) (p=0.05). This result was also 
found when we corrected for stage. 
Table 3. Survival analysis in 10 small cell lung cancer (SCLC) patients and 21 
controls according to DNA distribution.
Discussion
The results of this exploring study show a correlation between higher plasma 
DNA concentration and poorer survival in SCLC patients, which is in agreement 
with other studies4,8, but not all.9 Fournie et al. and Beau-Faller et al. used non 
quantitative detection, whereas nowadays qPCR for DNA quantification can 
be regarded as the standard method.11 Different genes can be used for DNA 
amplification, depending on the experience of the institute, and do not influence 
the amount of circulating DNA. In our institute a qPCR assay targeting the ß-globin 
gene performed consistently in other experiments and was used in the present 
study.7 
Interestingly, in our study the median DNA concentration of the patients who died 
within 10 months after diagnosis was notably higher compared with the patients 
who died after 10 months. As far as we know, this has not been shown before 
in SCLC patients. The median survival for patients treated for extensive SCLC 
is about 8-13 months.12 Determining the DNA concentration in a simple blood 
sample might be helpful in informing SCLC patients and discussing prognosis. This 
is supported by Hou et al. showing that a higher number of circulating tumor 
cells (CTCs) is related to survival.13 Until now, studies examining circulating DNA 
or circulating DNA derived epigenetic changes as prognostic factors for survival in 
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SCLC are limited. Assessing epigenetic changes in blood besides circulating DNA 
might be complementary in determining SCLC diagnosis and prognosis.4,14 The 
ultimate goal is to develop targeted therapy based on (epi)genetic markers and 
making progress in patient’s prognosis. 
In this study a significantly higher median DNA concentration with broader IQ 
range values was found in SCLC patients compared with the NSCLC patients in our 
previous study which is in agreement with others investigating circulating DNA 
as a diagnostic biomarker.7-9 Since NSCLC and SCLC differ in biology, treatment 
and prognosis, we hypothesized that the DNA concentration might differ between 
these two types of lung cancer. The circulating DNA is thought to originate from 
lysis, cell necrosis and apoptosis of cancer cells.5 Tumor volume doubling times 
obtained with X-thorax are considerable lower for SCLC compared with NSCLC 
(median time 65 days and 90-185 days, respectively).15 SCLC is morphologically 
characterized, besides a limited amount of cytoplasm, by a high number of 
mitoses (>50 / 2 mm2) and apoptotic figures.16 The rapid growth of SCLC involves 
a high turnover of tumor cells to apoptosis and lysis, and may explain why this 
leads to higher DNA levels compared with NSCLC patients. 
The limiting factor of our study is the small sample size. Of the lung cancer patients, 
only 10-15% have SCLC and the incidence is declining.1 Other studies concerning 
SCLC also described comparable patients numbers.8,9 Although in former NSCLC 
studies no relationship of age, sex or pulmonary inflammatory conditions with 
DNA concentration was found, our study is too small to investigate these relations 
and therefore, this has to be confirmed in future SCLC studies with larger number 
of cases, allowing subgroup analysis. 
Conclusion
We found increased quantities of circulating DNA in SCLC patients compared 
with controls and NSCLC patients with a state of the art qPCR technique. A 
high circulating plasma DNA concentration in SCLC patients was related to poor 
survival. Our results suggest that circulating DNA should be evaluated further as a 
potential prognostic biomarker in SCLC in larger studies.
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Summary
Lung cancer is considered as a major epidemic in the 20th en 21th century. It is 
the second most common cancer type in Dutch men and the third most common 
type in women and  the leading cause of death by cancer worldwide (www.ikcnet.
nl).1 The incidence of lung cancer in males is declining in developed countries 
following the significant  decreased tobacco consumption, but the proportion of 
females more than doubled from 15% in 1989 to 1993 to 34% in 2004 to 2009. In 
this thesis, an overview of changes treatment and prognosis of non-small cell lung 
cancer (NSCLC) and small cell lung cancer (SCLC) in the Netherlands in the last 20 
years is presented. Further, it has been investigated how biomarkers in different 
body fluids guide diagnosis and prognosis in lung cancer. 
Epidemiology of lung cancer
The majority (85-90%) of all lung cancers are NSCLC. In chapter 2, changes in 
treatment and prognosis of all NSCLC patients selected from the population-
based Netherlands Cancer Registry (NCR) were described in the period 1989 to 
2009 (n=147,760). Twenty-five percent of the patients was 75 years or older at 
the time of diagnosis. The proportion of NSCLC patients treated with standard 
of care therapy, as described in the Dutch guideline for staging and treatment of 
NSCLC published in 2004 (www.ikcnet.nl), increased in the past 20 years, except 
for stage II. The proportion of younger patients (< 75 years) with stage I undergoing 
surgery increased from 84% to 89% and among elderly (≥ 75 years) from 35% 
to 49%; for stage II this proportion decreased from 80% to 71% and remained 
about 25% in respectively the younger and older patients. Application of adjuvant 
chemotherapy for stage II increased to 24% in younger patients, but remained 
<5% among the elderly. Younger patients with stage III received chemoradiation 
more often up to 43% and up to 13% in elderly, compared with 8% and 1% in 1989 
to 1993, respectively. In stage IV, chemotherapy in younger patients increased 
from 10% to 54%, and in elderly from 5% to 21%. Five-year relative survival of the 
total group increased from 14.8% to 17.4%  and especially among females (18%), 
younger patients (18%) and within each stage, which could be partly explained by 
changes in treatment and partly by better staging. In conclusion, over a 20-year 
period, application of therapy in NSCLC patients, which is currently considered as 
standard, has improved. This has led to small improvements in survival within all 
stages.
Ten to fifteen percent of lung cancer consists of SCLC. Changes in treatment and 
survival in daily practice of SCLC in the Netherlands since 1989 were described in 
chapter 3 also using the population-based data from the NCR (n =34,100). The 
proportion of younger patients (< 75 years) with limited disease (LD) receiving 
chemoradiation, the current standard therapy, increased from 19% to about 65% 
in 2004 to 2009 and from 7% to 27% among elderly (≥ 75 years). Among patients 
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with extensive disease (ED) the proportion receiving chemotherapy remained 
stable over time (around 82% for younger patients and almost 50% for the elderly). 
Significant improvements in 1-year relative survival occurred for patients aged 45 
to 59 years, but not for the other age groups. Relative survival has significantly 
increased for both stage groups. In conclusion, application of standard of care 
therapy increased over time, but was less for elderly and for patients with 
limited disease. Despite better staging techniques and the use of new treatment 
modalities, survival of unselected patients with SCLC only improved for patients 
aged 45 to 59 years.
Biomarker analyses and DNA profiling in lung cancer
A suspected clinical and/or radiologic diagnosis of lung cancer needs to be 
confirmed by cytologic or histologic analysis. Mostly, a flexible bronchoscopy 
is performed including washings, brushings and forceps biopsies to establish 
lung cancer diagnosis. The diagnostic yield of bronchoscopy increases in larger 
tumors and endoscopic visible tumors. In chapter 4, the optimal timing and 
cost-effectiveness of washing relative to biopsy and brushing in bronchoscopy 
was analyzed prospectively in central (n=137) and peripheral (n=84) tumors of 
221 patients. The diagnostic yield of washings before biopsies and brushings did 
not differ from the diagnostic yield of washings after biopsies and brushings in 
central, visible tumors (about 73%) and peripheral, non-visible tumors (about 
39%). In 6% of the patients a diagnosis of malignancy was only established by 
washings. In case of a negative bronchoscopy, more invasive procedures were 
performed to establish a cancer diagnosis. Using known probabilities and costs for 
various bronchoscopic procedures, the expected utility of a number of diagnostic 
strategies was estimated including the invasive procedures. Confining laboratory 
investigations of washings or brush samples to those cases where initial findings 
of the biopsies are negative (the two-stage procedure) is more cost-effective than 
examining biopsies, brushings and washings altogether. In patients with visible 
tumors, brushing or washing in addition to biopsy is equally cost-effective; in 
patients with non-visible tumors, biopsy combined with washing is the preferred 
option. Apparently no difference in the diagnostic yield could be demonstrated 
for washings before or after biopsies and brushings. Although the additional 
diagnostic yield of washing and brushing during bronchoscopy is relatively low, 
it is cost-effective to use these procedures in the diagnostic work-up of patients 
who are clinically suspected of having a pulmonary malignancy.
Increasingly, molecular markers in bronchial washings are investigated to improve 
the diagnostic yield of peripheral, endoscopic non-visible, tumors. In chapter 5, 
the diagnostic value of RASSF1A methylation and KRAS mutations in washings 
in nondiagnostic bronchoscopy was analyzed in 51 patients with suspected lung 
cancer who had peripheral tumors and compared with 28 controls without a 
cancer diagnosis. The proportion of RASSF1a methylation was significantly higher 
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in central and larger  tumors. In patients with nondiagnostic bronchoscopy (n=17), 
RASSF1A methylation was detected in the washings of 4 patients (24%), and KRAS 
mutations were detected in the washings of  2 patients (12%). In total, 29% of 
the false-negative or doubtful cytology results were accompanied by RASSF1A 
methylation or KRAS mutation results that were highly suggestive of malignancy. 
No relevant RASSF1A methylation was detected in control samples. These data 
suggest that the molecular analysis of 2 biomarkers in nondiagnostic bronchial 
washings may better guide diagnostic procedures in patients with suspected lung 
cancer. 
Besides bronchoscopy, cytologic analysis of sputum can be used in the diagnostic 
work-up of lung cancer. Because the average diagnostic yield of sputum cytology 
is modest, also molecular markers are increasingly investigated in the (early) 
diagnosis of lung cancer. Therefore, the aim of chapter 6 was to examine the 
presence of free DNA in sputum and its relationship to the presence of lung 
cancer. Free, or circulating DNA, is present in considerably higher concentrations 
in plasma of lung cancer patients compared with healthy controls or patients 
with benign disease. Free DNA was detected in sputum samples of 28 lung cancer 
patients and 68 controls without differences in DNA concentration. For all patients 
combined the amount of free DNA was related to the amount of inflammation. To 
discriminate between tumor related free DNA and inflammation, hypermethylation 
of RASSF1A was assessed. Increased hypermethylation of RASSF1A was found in 
lung cancer patients compared with controls. In conclusion, the amount of free 
DNA in sputum appeared to be related to the amount of inflammation, but not to 
the presence of lung cancer.
Although many studies report about the diagnostic value of circulating DNA in 
lung cancer, conflicting data are reported its prognostic value. Therefore, the aim 
of chapter 7 was to prospectively analyze the relationship of circulating plasma 
DNA with overall survival (OS) of previously untreated non-small cell lung cancer 
(NSCLC) patients (n=46). The median baseline DNA concentration, quantitated 
by a real-time quantitative polymerase chain reaction (qPCR) targeting the 
human-globin gene, of the NSCLC patients who died (87%) was significantly 
higher compared with the patients that survived at the end of a follow-up time 
of 6.5 years (55 ng/ml versus 23 ng/ml, p = 0.02). In patients with higher DNA 
concentration overall survival was significantly worse. In this study no relation 
of DNA concentration with tumor characteristics, age, gender or pulmonary 
inflammatory conditions was found. In conclusion, a high circulating plasma DNA 
concentration at time of diagnosis in NSCLC patients was a prognostic factor 
for poorer survival. As little is known about the prognostic value of circulating 
DNA in SCLC patients, circulating plasma DNA as a prognostic factor for survival 
was analyzed prospectively in SCLC in chapter 8. In this small exploring study a 
correlation between higher plasma DNA concentration and poorer survival in 10 
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SCLC patients was found (p = 0.04, HR 1.6). The median DNA concentration of the 
patients that died within 10 months after diagnosis (n=6) was higher compared 
with the patients that died after 10 months (n=4) (p=0.05). Circulating DNA in 
SCLC patients should be further evaluated as a potential prognostic biomarker. 
General discussion
The traditionally poor prognosis of lung cancer is accompanied by a considerable 
proportion of advanced stage at the time of diagnosis, which increased 
significantly in the last 20 years. Currently, (more than) half of the population of 
NSCLC and SCLC patients have advanced disease (this thesis). In the last decade, 
stage migration occurred as a result of improved diagnostic techniques, such as 
improved availability and quality of computerized tomography (CT) scans and 
fluorodeoxyglucose-positron emission tomography (FDG-PET) scanning. With 
the availability of these techniques the detection of previously occult distant 
metastases is facilitated, which has led to an upstaging from early to advanced 
disease.2,3 Minimally invasive techniques such as esophageal or endobronchial 
endoscopic ultrasound enhanced the accuracy of mediastinal staging and also 
changes in the TNM (tumor, node, metastasis) classification system in 1997 have 
attributed to a stage-shift.4-6 Increasingly, refinements of the diagnostic yield of 
bronchoscopy, sputum and plasma including assessment of molecular markers 
are under investigation to improve lung cancer diagnosis. Molecular analysis in 
body fluids could be particularly useful for patients with advanced lung cancer in 
whom cytologic specimens are often the only materials available. In this thesis 
was investigated how bronchial washings, RASSF1A methylation and circulating 
DNA in different body fluids facilitate in diagnosing lung cancer. 
Biomarker analyses and DNA profiling in lung cancer
Bronchial washings
Bronchoscopy is an invaluable diagnostic tool in the diagnosis and staging of lung 
cancer.7,8 Bronchoscopic biopsies of central tumors provide a high yield of 71 to 
91%. Since the additional diagnostic yield of brushings and washings in these 
tumors is modest, one might consider omitting these procedures altogether 
restricting the increasing costs of lung cancer diagnosis in the current health 
care system. However, a negative bronchoscopy implicates additional invasive 
diagnostic procedures with increased health care risk and costs. In this thesis was 
shown that confining the cytologic investigations of washings or brushings only in 
patients with a nondiagnostic biopsy was most cost-effective. The same result was 
found in patients with peripheral tumors. Bronchoscopic biopsies of peripheral 
tumors provide a lower yield of about 36 to 61%. Brushings and washings increase 
the diagnostic yield to a modest extent. Biopsies combined with washings was the 
most cost-effective in peripheral tumors. In both central and peripheral tumors 
the timing of washings did not influence the diagnostic yield. Considering logistic 
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aspects, one can perform all techniques to  obtain material for the pathologist, but 
work cost-effectively by investigating washings or brushings only if the biopsy is 
not diagnostic. However, considering patient aspects and current quality indicators 
demanding short waiting times for diagnostic procedures and treatment, one can 
investigate all material as fast as possible.9 It also gives opportunity to analyze 
additional molecular analysis. 
RASSF1A methylation and KRAS mutation
Methylation analysis in (lung) cancer is upcoming. Besides RASSF1A methylation, 
other methylated genes are described such as p16, FHIT, O-6-methylguanine-
DNA methyltransferase (MGMT) and death-associated protein kinase (DAPK).10-
13 Methylation of more than one of these genes occurs frequently and seems 
an important phenomenon in silencing tumor suppressor genes. Assays for 
the detection of hypermethylation have several advantages: abnormal DNA 
methylation represents a stable tumor-associated marker, DNA methylation 
occurs mainly at specific CpG islands and with a methylation-specific (MSP) PCR 
the methylation status of CpG sites can rapidly be assessed with a high sensitivity 
and specificity.14,15 Hypermethylation and KRAS mutations can be found in tumor 
tissue and various body fluids such as sputum and bronchial washings (this 
thesis).16,17 Both have shown to be early events in the development of lung cancer. 
12 The diagnostic value of these parameters were analyzed in washings of central 
and peripheral tumors. In line with other studies, the additional diagnostic value 
in central tumors is limited due to the already high yield of common cytologic 
and histologic analysis of bronchoscopic sampling.18 In peripheral tumors 
with nondiagnostic bronchcoscopy was found that the detection of RASSF1A 
methylation in bronchial washings provides important evidence to suggest 
malignancy in patients suspected of NSCLC. Considering the above, we suggest 
that the bronchoscopic work-up for peripheral tumors may consist of performing 
biopsies and washings. The pathologist may perform a step by step analyses: if 
biopsies are negative, cytologic analysis of washings is performed, and if negative, 
RASSF1A analysis is performed. If positive, additional invasive procedures should 
be performed until lung cancer diagnosis is made definitely. If not, it depends 
on symptoms and radiologic signs if either further diagnostic procedures are 
necessary, or to perform evaluation chest CT-scan after 3 months. The presence 
of RASSF1A methylation is highly suggestive of lung cancer. In several studies, the 
amount of RASSF1A hypermethylation in patients with lung cancer is much higher 
than the low proportion of methylation in controls (0-4%).16,18,19 This difference 
may allow a threshold level to be set. Besides facilitating in diagnosing lung 
cancer, RASSF1A methylation appears to be related to unfavorable prognosis.13,20,21 
Hypermethylation seems to be reversible by pharmacologic agents. Further 
studies to anti-lung cancer drugs aimed at RASSF1A methylation are ongoing.
Besides RASSF1A methylation analysis, the diagnostic value of KRAS mutations in 
washings of patients with peripheral tumors was analyzed. Because it is known 
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that KRAS mutations appear in tumor cells and not in healthy subjects, the 
presence of KRAS mutations indicate an increased  probability of cancer cells.22 
However, KRAS mutations are predominantly found in adenocarcinomas (about 
30%), which occur in about a third of the NSCLC patients. Thus, the prevalence 
of  KRAS mutations in NSCLC is not high. In line with other studies, the additional 
value of KRAS mutation analysis in the washings of nondiagnostic bronchoscopy 
was limited.23,24  Although the diagnostic value of KRAS mutations is limited, it 
is considered as a poor prognostic factor. KRAS mutations are associated with 
resistance to chemotherapy and targeted therapy aimed at the epidermal growth 
factor receptor (EGFR).25,26 
Circulating DNA
Molecular changes, such as point mutations, microsatellite alterations and 
hypermethylated sequences, can also be found in extracellular DNA besides 
tumor cells. Extracellular or circulating DNA is increased in plasma of cancer 
patients as compared with healthy controls or patients with benign disease, but it 
is not cancer specific.27-29 So, finding increased quantities of circulating in plasma 
is highly suspective of cancer, but needs to be confirmed by cytologic or histologic 
analysis. Therefore, the diagnostic value of circulating plasma DNA for lung cancer 
patients is limited in daily practice, although interesting in combination with 
other clinical parameters and/or qualitative molecular markers.14,30,31 Until now, 
the presence of extracellular DNA in sputum and its relationship to lung cancer 
was unknown. We found that free DNA was present in sputum samples of the 
cancer patients and controls and related to the amount of inflammation, but not 
to the presence of cancer (this thesis). Further, increased hypermethylation of 
RASSF1A in lung cancer patients compared with controls was found to show that 
tumor related DNA is present in sputum. Sputum cytology does not play a role 
in early detection of lung cancer yet, but is of increasing interest in combination 
with low dose CT in large screening studies.32-35 If lung cancer could be detected 
earlier, treatment and prognosis might be improved. 
In spite of the reservations about the diagnostic capacities of circulating DNA, it 
offers potential utility as a prognostic biomarker. Circulating DNA may be used as 
a non-invasive biomarker to refine the prognostic profile in NSCLC and possibly 
in SCLC patients. The results in this thesis show that a high circulating plasma 
DNA concentration correlates with poor survival in NSCLC patients and perhaps 
in SCLC patients. No relationship of DNA concentration with clinical parameters 
as age, gender, histology, stage and smoking was found. Also no correlation 
with pulmonary inflammatory conditions was found in contrast to our sputum 
analysis. Recent studies also show that circulating plasma DNA is a prognostic 
factor for survival in NSCLC, but the clinical value remains controversial.30,36,37 
There are several limitations about circulating DNA. First, in guiding prognosis 
we are dealing with a broad range of circulating DNA, it is not an on-and-off 
phenomenon. The need for a valid cut-off value is clear, but not established 
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yet. Since circulating DNA is analyzed with different techniques, such as qPCR, 
pico green quantification and radioimmunoassay, and with different targeting 
genes, it is difficult to define a cut-off value which is valid for all NSCLC patients 
worldwide.38-40 Also, the significance of a DNA concentration just above the cut-
off value is doubtful. So, it may be valuable for a group of patients, but not for 
the individual patient yet. With increased refinements in predictive markers and 
personalized treatment, the role of circulating DNA as a predictive marker needs 
to be explored. In the last years, several studies showed that circulating DNA was 
predictive of the response to chemotherapy, but not to targeted therapy.30,37,41,42 
Besides extracellular DNA, circulating tumor cells (CTC’s) can be found in 
plasma.43 Studies in breast, prostate and colorectal cancer have demonstrated 
the prognostic significance of CTC’s. Recently, an increased number of CTC’s was 
found in stage IV lung cancer patients and correlated with worse survival.44,45 Data 
interpretation is difficult due to variation in detection methods and reproduction 
across laboratories, comparable with the extracellular DNA studies. Finding the 
true boundaries of clinical opportunities for both circulating DNA and CTC’s is a 
repeating challenge.
Population-based survival studies in lung cancer
Besides the prognostic value of circulating plasma DNA for survival of lung cancer 
patients, changes in survival according to treatment in the last 20 years was part 
of this thesis. Five-year relative survival of all patients with NSCLC together in 
the Netherlands improved slightly since 2004/5. In SCLC 1-year relative survival 
improved for patients aged 45 to 59 years, but not for the other age groups. 
Stage migration contributed to the observed small improvements in survival 
within all stages.46 Also better compliance to treatment strategies with clinical 
service standards such as guidelines could have contributed to better survival at 
population level.47 Although application of standard of care therapy increased 
over time, it was significantly less for elderly. Both therapy and survival results 
in clinical trials, including younger patients with good performance status, is still 
at a distance from the application of therapy and survival data observed in daily 
practice in unselected patients. Here, evidence based medicine meets patient 
based medicine. Individual treatment choices are limiting survival in elderly, driven 
for example by comorbidity and fulfilled life expectancy. The young, however, are 
subject to strict protocols driving them to prolonged survival.
Although multiple molecular biomarkers are under investigation as prognostic 
and predictive factors for survival, new personalized treatment strategies are 
developed and physicians act increasingly according to the current treatment 
guidelines. Physicians and researchers are increasingly aware of the positive 
effect on survival of psychosocial support and palliative care.48 Metastatic lung 
cancer is a debilitating disease that results in a high burden of symptoms and 
poor quality of life. In palliative care, with its focus on management of symptoms, 
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psychosocial support, and assistance with decision making, the quality of care 
can be improved with lower rates of depressive symptoms and lower use of 
medical services. Optimal integration of psychosocial support and palliative care 
with standard oncologic care in patients with lung cancer should be the focus in 
oncologic clinical practice and future research.
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De diagnose longkanker geeft een hoge ziektelast bij patiënten en is de 
belangrijkste doodsoorzaak door kanker wereldwijd (www.ikcnet.nl).1 Het is 
het 2e meest voorkomende kankertype bij Nederlandse mannen en het 3e bij 
vrouwen. In de Westerse landen neemt de incidentie van longkanker bij mannen 
af door een verminderd tabaksgebruik, maar het aantal vrouwen met longkanker 
is verdubbeld van 15% in 1989-93 tot 34% in 2004-09. In dit proefschrift wordt een 
overzicht gegeven van de veranderingen in behandeling en overleving van niet-
kleincellig longkanker (NSCLC) en kleincellig longkanker (SCLC) in Nederland in de 
laatste 20 jaar (hoofdstukken 2 en 3). Daarnaast is de bijdrage van biomarkers in 
verschillende lichaamsvloeistoffen in de diagnostiek en prognose van longkanker 
onderzocht (hoofdstukken 4, 5, 6, 7 en 8). 
Epidemiologie van longkanker
Het merendeel van de longkankerpatiënten heeft niet-kleincellig longkanker (85-
90%). In hoofdstuk 2 worden veranderingen beschreven in de behandeling en 
prognose van alle niet-kleincellig longkankerpatiënten in Nederland, verzameld in 
de landelijke database van de Nederlandse Kanker Registratie (NKR), in de periode 
1989-2009 (n=147.760). Op het moment van diagnose was 25% van de patiënten 
≥ 75 jaar. Het aantal niet-kleincellig longkankerpatiënten behandeld met de 
huidige standaardbehandeling, zoals beschreven in de Nederlandse richtlijn voor 
stadiëring en behandeling van niet-kleincellig longkanker (2004, www.ikcnet.nl), 
is toegenomen in de laatste 20 jaar, behalve voor stadium II. Het aantal jongere 
patiënten (< 75 jaar) behandeld met chirurgie in stadium I nam toe van 84% tot 
89% en bij ouderen (≥ 75 jaar) van 35% tot 49%; in stadium II daalde dit aantal van 
80% tot 71% bij jongere patiënten en bleef rond 25% bij ouderen. De toepassing 
van adjuvant chemotherapie in stadium II bij jongere patiënten nam toe tot 24%, 
maar bleef < 5% bij ouderen. In stadium III steeg de proportie jongere patiënten 
behandeld met chemoradiatie van 8% tot 43% en bij ouderen van 1% tot 13%. 
De proportie jongere patiënten met stadium IV behandeld met  chemotherapie 
nam toe van 10% tot 54%, en bij ouderen van 5% tot 21%. De 5-jaars relatieve 
overleving van de totale groep steeg van 14.8% tot 17.4% en vooral bij vrouwen 
(18%), jongere patiënten (18%) en binnen elk stadium, wat verklaard kon 
worden door zowel veranderingen in behandeling als door een betere stadiëring. 
Concluderend is de toepassing van de huidige standaard behandeling voor niet-
kleincellig longkanker gedurende de laatste 20 jaar verbeterd. Dit heeft geleid tot 
kleine verbeteringen in overleving binnen alle stadia. 
Tien tot 15% van de longkankerpatiënten heeft kleincellig longkanker. 
Veranderingen in de periode 1989-2009 in de behandeling en prognose van alle 
kleincellig longkanker patiënten in Nederland, eveneens verzameld in de NKR, 
zijn beschreven in hoofdstuk 3 (n =34.100). De proportie jongere patiënten 
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(< 75 jaar) met een vroeg stadium, limited disease, behandeld met de huidige 
standaard behandeling met chemoradiatie nam toe van 19% tot ~65% in 2004-
2009 en bij ouderen (≥ 75 jaar) van 7% tot 27%. Het aandeel patiënten met 
een gevorderd stadium, extensive disease, behandeld met chemotherapie 
veranderde niet gedurende 20 jaar (~82% van de jongere patiënten en ~50% 
van de ouderen). De 1-jaars relatieve overleving van patiënten tussen 45-59 jaar 
verbeterde significant, maar niet voor de andere leeftijdsgroepen. De relatieve 
overleving verbeterde significant voor beide stadia. Concluderend is het gebruik 
van de huidige standaard behandeling van kleincellig longkanker in de laatste 20 
jaar verbeterd, maar minder duidelijk voor ouderen en patiënten met limited 
disease. Ondanks verbeterd stadiëringsonderzoek en het gebruik van verbeterde 
en nieuwe behandelcombinaties, is de overleving van ongeselecteerde kleincellig 
longkanker patiënten alleen verbeterd voor de leeftijdsgroep 45-59 jaar.
Biomarker en DNA analyse in lichaamsvloeistoffen bij longkanker
Een klinische of radiologische verdenking op longkanker moet bevestigd worden 
met cytologisch of histologisch onderzoek. Materiaal wordt vaak verkregen via een 
flexibele bronchoscopie waarbij spoelingen, brush (borsteltechniek) en biopten 
worden verricht. De diagnostische opbrengst van een bronchoscopie neemt toe 
bij grotere tumoren en bij endobronchiaal zichtbare tumoren. In hoofdstuk 4 is 
de optimale timing en kosten-effectiviteit van spoelingen in relatie tot biopten 
en brush tijdens bronchoscopie prospectief onderzocht bij centrale (n=137) en 
perifere (n=84) tumoren van 221 patiënten. De diagnostische opbrengst van 
spoelingen voor biopten en brush verschilde niet van de diagnostische opbrengst 
van spoelingen na biopten en brush bij centrale, zichtbare tumoren (~ 73%) en 
bij perifere, niet-zichtbare tumoren (~ 39%). Bij 6% van de patiënten werd alleen 
op basis van spoelingen de diagnose kanker gesteld. Indien de bronchoscopie 
geen diagnose van kanker  opleverde, werd meer invasief onderzoek verricht. 
De verwachte meerwaarde van het aantal diagnostische strategieën inclusief de 
invasieve procedures werd geschat met behulp van de bekende kosten van de 
diverse bronchoscopische procedures. Het laboratoriumonderzoek van spoelingen 
en brush beperken tot de patiënten waarbij de biopten negatief zijn (de twee-staps 
procedure) is kosteneffectiever dan alle biopten, brush en spoelingen gezamenlijk 
onderzoeken. Bij patiënten met zichtbare tumoren is het toevoegen van ofwel 
brush ofwel spoelingen aan biopten even kosteneffectief; bij patiënten met niet-
zichtbare tumoren heeft biopten gecombineerd met spoelingen de voorkeur. 
Deze resultaten tonen dat er geen verschil is in diagnostische opbrengst tussen 
spoelingen voor of na het nemen van biopten en brush. Hoewel de toegevoegde 
waarde van spoelingen en brush tijdens een bronchoscopie relatief beperkt is, is 
het kosteneffectief om deze procedures toe te passen tijdens de diagnostische 
work-up van patiënten met verdenking op een pulmonale maligniteit.
In toenemende mate worden moleculaire markers in endobronchiale spoelingen 
onderzocht om de diagnostische opbrengst van perifere, niet-zichtbare 
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tumoren te verbeteren. In hoofdstuk 5 is de diagnostische waarde van RASSF1A 
methylering  en KRAS mutaties onderzocht in spoelingen van niet-diagnostische 
bronchoscopiëen bij 51 patiënten met verdenking op longkanker met perifere 
tumoren. Dit is vergeleken met 28 controle patiënten zonder maligniteit. De 
proportie RASSF1a methylering was significant hoger in centrale en grotere 
tumoren. Bij patiënten met een niet-diagnostische bronchoscopie (n=17) werd 
RASSF1A methylering gevonden in de spoelingen van of 4 patiënten (24%), en 
KRAS mutaties werden gevonden in de spoelingen van 2 patiënten (12%). In totaal 
ging 29% van de vals negatieve of twijfelachtige cytologie resultaten gepaard met 
RASSF1A methylering of KRAS mutaties met hoge verdenking op een maligniteit. 
Er werd geen relevante RASSF1A methylering gevonden bij controle patiënten. 
Deze resultaten suggereren dat de moleculaire analyse van 2 biomarkers bij niet-
diagnostische bronchiale spoelingen leidend kunnen zijn in verdere diagnostische 
procedures bij patiënten met verdenking longkanker. 
Naast bronchoscopie kan cytologische sputumanalyse worden gebruikt in 
het diagnostisch traject van longkanker. Omdat de gemiddelde opbrengst van 
sputumcytologie bescheiden is, wordt in toenemende mate de diagnostische 
waarde van moleculaire markers in sputum geanalyseerd. Hoofdstuk 6 beschrijft 
een studie naar de aanwezigheid van vrij, of extracellulair, DNA in sputum en de 
relatie tot longkanker. Extracellulair, of circulerend, DNA komt in aanzienlijk hogere 
concentraties voor in plasma van (long)kankerpatiënten vergeleken met gezonde 
controles of patiënten met een goedaardige aandoening. Extracellulair DNA 
werd gevonden in sputum monsters van 28 longkankerpatiënten en 68 controle 
patiënten  zonder verschil in DNA concentratie. In de hele groep was extracellulair 
DNA gerelateerd aan de mate van inflammatie. Toegenomen methylering van 
RASSF1A werd gevonden bij longkankerpatiënten in vergelijking met controle 
patiënten  ter onderscheiding van tumor gerelateerd DNA met extracellulair 
DNA door inflammatie. Op basis van deze resultaten werd geconcludeerd dat 
de hoeveelheid extracellulair  DNA in sputum gerelateerd is aan de mate van 
inflammatie, maar niet aan de aanwezigheid van longkanker.
Hoewel in veel studies de diagnostische waarde van circulerend DNA in 
longkanker is onderzocht, zijn er tegenstrijdige resultaten over de prognostische 
waarde van circulerend DNA. Het doel van hoofdstuk 7 was om prospectief te 
onderzoeken wat de relatie van circulerend DNA met de overleving is bij 46 
niet-kleincellig longkankerpatiënten. De baseline DNA concentratie, afgenomen 
voor behandeling, werd bepaald door een real-time quantitatieve polymerase 
chain reactie (qPCR) op het humane beta-globine gen. De DNA concentratie van 
de overleden niet-kleincellig longkankerpatiënten (87%) was significant  hoger 
vergeleken met de patiënten nog in leven aan het einde van de follow-up tijd 
van 6.5 jaar (55 ng/ml versus 23 ng/ml, p = 0.02). De overleving van patiënten 
met een hoge DNA concentratie was significant slechter. In deze studie werd geen 
relatie gevonden tussen de DNA concentratie en tumor karakteristieken, leeftijd, 
geslacht of pulmonaal inflammatoire condities. Geconcludeerd werd dat een 
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hoge circulerend DNA concentratie in plasma op het moment van de diagnose 
niet-kleincellig longkanker een prognostische factor is voor slechte overleving. 
Aangezien er weinig bekend is over circulerend DNA als prognostische waarde voor 
overleving van kleincellig longkankerpatiënten, werd dit prospectief onderzocht 
in hoofdstuk 8. In deze kleine explorerende studie werd een correlatie gevonden 
tussen een hogere  plasma DNA concentratie en slechte overleving bij 10 
kleincellig longkankerpatiënten (p = 0.04, HR 1.6). De mediane DNA concentratie 
van de patiënten die binnen 10 maanden na diagnose overleden (n=6) was hoger 
vergeleken met de patiënten die overleden na 10 maanden (n=4) (p=0.05). 
Circulerend DNA dient verder onderzocht te worden in toekomstig onderzoek als 
potentiële prognostische biomarker  bij kleincellig longkanker patiënten. 
Algemene discussie
De slechte prognose van longkanker wordt in belangrijke mate veroorzaakt door 
een groot percentage gevorderd stadium op het moment van diagnose. Dit 
percentage is significant toegenomen in de laatste 20 jaar en vandaag de dag heeft 
meer dan de helft van de niet-kleincellig en kleincellig longkankerpatiënten een 
gevorderd stadium (dit proefschrift). In de laatste 10 jaar vond stadiummigratie 
plaats als een gevolg van verbeterde diagnostische  technieken, zoals toegenomen 
beschikbaarheid en kwaliteit van computerized tomography (CT) scans en 
positron emissie tomografie (PET) scans. Dankzij deze technieken is de ontdekking 
van eerder niet zichtbare metastasen op afstand toegenomen, wat ertoe heeft 
geleid dat een aanzienlijk aantal patiënten met aanvankelijk een vroeg stadium, 
een gevorderde stadium bleek te hebben.2,3 Minimaal invasive techniqen 
zoals slokdarm- of endobronchiale endoscopische echografie verbeterde de 
nauwkeurigheid van mediastinale stadiëring. Daarnaast hebben veranderingen in 
de TNM classificatie 1997 bijgedragen aan veranderingen in stadiëring.4-6 
In toenemende mate vindt verfijning van de diagnostiek plaats om de diagnose 
longkanker makkelijker te kunnen stellen, inclusief analyse van moleculaire 
markers. Moleculaire analyse in lichaamsvloeistoffen kan vooral van toegevoegde 
waarde zijn bij patiënten met gevorderd longkanker bij wie vaak cytologisch, maar 
geen histologisch materiaal beschikbaar is. In dit proefschrift is onderzocht hoe 
bronchiale spoelingen, RASSF1A methylering en circulerend DNA in verschillende 
lichaamsvloeistoffen kunnen bijdragen aan de diagnose en prognose van 
longkanker. 
Biomarker analyse van longkanker in lichaamsvloeistoffen
Bronchiale spoelingen
Bronchoscopie is een belangrijk diagnostisch instrument in de diagnose en stadiëring 
van longkanker.7,8 Bronchoscopische biopten van centrale  tumoren hebben een 
hoge opbrengst (71% tot 91%). Aangezien de toegevoegde diagnostische waarde 
van brush en spoelingen in deze tumoren bescheiden is, kan men overwegen om 
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deze procedures achterwege te laten en hiermee de toenemende kosten in de 
huidige gezondheidszorg in de diagnostiek van longkanker te beperken. Echter, 
een negatieve bronchoscopie leidt tot aanvullende invasieve diagnostische 
procedures met als gevolg toegenomen gezondheidsrisico’s en kosten. De 
resultaten van de studie in hoofdstuk 4 laten zien dat het uitvoeren van een 
cytologische analyse van brush en spoelingen alleen bij patiënten met een niet-
diagnostisch weefselonderzoek het meest kosteneffectief is. Een vergelijkbaar 
resultaat werd gevonden bij  patiënten met perifere tumoren. Bronchoscopische 
biopten van perifere tumoren hebben een lagere opbrengst (36 to 61%). Brush 
en spoelingen verhogen de diagnostische opbrengst in beperkte mate. Het meest 
kosteneffectief in perifere tumoren was het nemen van biopten gecombineerd 
met spoelingen. De timing van spoelingen had geen invloed op de diagnostische 
opbrengst van zowel centrale als perifere tumoren. De logistieke aspecten in acht 
nemende, kan men alle technieken uitvoeren om materiaal te verzamelen voor 
de patholoog, maar kosteneffectief te werken door brush en spoelingen alleen na 
te kijken indien de biopten niet conclusief zijn. Als we anderzijds rekening houden 
met de huidige kwaliteitsindicatoren betreffende korte doorlooptijden voor 
diagnostiek en behandeling, moet al het materiaal zo snel mogelijk onderzocht 
worden.9 Dit biedt ook mogelijkheden om moleculaire markers aanvullend te 
onderzoeken. 
RASSF1A methylering en KRAS mutatie
In toenemende mate wordt methylering in (long)kanker onderzocht. Behalve 
RASSF1A methylering, zijn andere gemethyleerde genen beschreven zoals p16, 
FHIT, O-6-methylguanine-DNA methyltransferase (MGMT) en death-associated 
protein kinase (DAPK).10-13 Methylering van één of meer van deze genen komt 
vaak voor en blijkt een belangrijk fenomeen te zijn in het stilleggen van tumor 
suppressor genen. Het gebruik van hypermethyleringstechnieken heeft diverse 
voordelen: abnormale  DNA methylering vertegenwoordigt een stabiele tumor-
geassocieerde marker, DNA  methylering vindt vooral plaats op specifieke CpG 
eilandjes en de methyleringsstatus van deze CpG eilandjes kan snel worden 
bepaald met een methylerings-specifieke (MSP) PCR met een hoge sensitiviteit 
en specificiteit.14,15 
Hypermethylering en KRAS mutaties kunnen zowel in tumorweefsels als in 
verschillende lichaamsvloeistoffen zoals sputum en bronchiale spoelingen 
worden gevonden (dit proefschrift).16,17 Beide veranderingen blijken vroeg in de 
ontwikkeling van longkanker voor te komen.12 In hoofdstuk 5 is de diagnostische 
waarde van deze parameters onderzocht in spoelingen van centrale en perifere 
tumoren. Zoals ook in andere studies is gevonden, bleek de toegevoegde 
diagnostische waarde in  centrale tumoren beperkt door de reeds hoge 
opbrengst van regulier cytologisch en histologisch bronchoscopisch onderzoek.18 
In niet-diagnostische bronchcoscopiëen van perifere tumoren bleek dat door de 
aanwezigheid van RASSF1A methylering in bronchiale spoelingen de verdenking 
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op niet-kleincellig longkanker toenam.
Gebaseerd op deze resultaten kan de diagnostiek van perifere longtumoren 
als volgt worden uitgewerkt. Tijdens een bronchoscopie worden biopten en 
spoelingen afgenomen. De patholoog onderzoekt alleen de cytologische monsters 
van de spoelingen indien de biopten negatief zijn. Indien de cytologie ook negatief 
is, wordt een  RASSF1A methyleringsanalyse uitgevoerd. Indien positief, dan volgt 
zoveel aanvullend invasief onderzoek totdat de diagnose longkanker definitief 
gesteld is. Indien negatief, dan hangt het van de symptomen en beeldvorming 
(CT- en PET-scan) af of aanvullend diagnostisch onderzoek wordt verricht, of 
dat de afwijkingen na 3 maanden worden geëvalueerd middels een CT-scan. 
De aanwezigheid van  RASSF1A methylering is sterk suggestief voor diagnose 
longkanker. In diverse studies was de mate van RASSF1A methylering in patiënten 
met longkanker veel hoger dan de lage hoeveelheid methylering in controle 
patiënten (0-4%).16,18,19 Dit maakt het noodzakelijk om een drempelwaarde vast 
te stellen in verder onderzoek. Naast de toegevoegde waarde in de diagnostiek, 
is  RASSF1A methylering ook gerelateerd aan een ongunstige prognose 
van longkanker.13,20,21 Hypermethylering kan worden teruggedraaid door 
farmacologische stoffen en onderzoek naar anti-longkanker medicatie gericht op 
RASSF1A methylering is gaande.
Naast RASSF1A methyleringsanalyse, is in hoofdstuk 5 de diagnostische 
waarde van KRAS mutaties in spoelingen van patiënten met perifere tumoren 
onderzocht. Aangezien bekend is dat KRAS mutaties wel in tumorcellen maar 
niet in gezonde controle patiënten voorkomen, duidt de aanwezigheid van KRAS 
mutaties op de aanwezigheid van kanker.22 De prevalentie van KRAS mutaties in 
longkanker is echter niet hoog, omdat KRAS mutaties vooral worden gevonden 
in adenocarcinomen (~ 30%), die ongeveer een derde van de niet-kleincellige 
longtumoren bedragen. Zoals ook ander onderzoek toont, was in onze studie 
de toegevoegde waarde van KRAS mutatie analyse in spoelingen van een niet-
diagnostische bronchoscopie beperkt.23,24 Hoewel de diagnostische waarde van 
KRAS mutaties beperkt  is, worden KRAS mutaties beschouwd als een ongunstige 
prognostische  factor. Deze aanwezigheid heeft consequenties voor behandeling, 
omdat KRAS mutaties gepaard kunnen gaan met resistentie voor chemotherapie 
en doelgerichte therapie gericht op de epidermale groei factor receptor (EGFR).25,26 
Circulerend DNA in sputum en plasma
Moleculaire veranderingen, zoals puntmutaties, microsatellite veranderingen en 
gehypermethyleerde sequenties, kunnen zowel in tumorcellen als in extracellulair 
DNA gevonden worden. Extracellulair, ook genoemd vrij of circulerend, DNA is 
vermoedelijk afkomstig van afgebroken cellen en is verhoogd in plasma van 
kankerpatiënten in vergelijking met gezonde controle patiënten  of patiënten 
met een goedaardige ziekte, maar is niet specifiek voor kanker.27-29 Verhoogde 
hoeveelheden circulerend DNA in plasma zijn sterk verdacht voor kanker, maar 
dit moet cytologisch of histologisch bevestigd worden. Hoewel in de dagelijkse 
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klinische praktijk de diagnostische waarde van circulerend plasma DNA voor 
longkanker patiënten nog beperkt is, is dit interessant om verder te onderzoeken 
in combinatie met andere klinische parameters en/of moleculaire markers.14,30,31 
Tot op heden is onbekend of extracellulair DNA in sputum aanwezig is en of er 
een relatie is met longkanker. Uit ons onderzoek bleek dat extracellulair DNA 
inderdaad aanwezig was in sputum monsters van kankerpatiënten. In vergelijking 
met controle patiënten werd bij kankerpatiënten verhoogde methylering van 
RASSF1A werd gevonden om aan te tonen dat dit DNA tumor gerelateerd is. 
Zowel bij kankerpatiënten als controle patiënten  was de hoeveelheid DNA 
echter gerelateerd aan inflammatie en niet aan kanker. Sputum cytologie en/
of moleculaire veranderingen spelen nog geen rol in de vroege opsporing van 
longkanker, maar staan in toenemende mate in de belangstelling in grote 
screeningsstudies in combinatie met lage dosis CT.32-35 Als longkanker eerder kan 
worden opgespoord, kunnen de behandeling en prognose worden verbeterd. 
Ondanks de klinisch diagnostische beperkingen van circulerend DNA, biedt het 
mogelijkheden als prognostische biomarker. Circulerend DNA kan worden gebruikt 
als een non-invasieve biomarker om het prognostische profiel van patiënten met 
niet-kleincellig longkanker en mogelijk met kleincellig longkanker te verfijnen. 
De resultaten van dit proefschrift tonen dat een hoge circulerend plasma DNA 
concentratie correleert met slechte overleving van patiënten met niet-kleincellig 
longkanker and mogelijk ook met kleincellig longkanker. Er werd  geen relatie 
gevonden tussen de DNA concentratie en klinische en tumor karakteristieken, en 
evenmin met inflammatoire condities in tegenstelling tot onze sputumanalyse. 
Recente studies tonen ook dat circulerend DNA een prognostische factor voor 
overleving is voor patiënten met niet-kleincellig longkanker, maar de waarde voor 
de klinische praktijk blijft controversieel.30,36,37 Ten eerste heeft circulerend DNA 
als prognostische marker  een ruime range aan waarden, het is geen aan-uit-
fenomeen. De noodzaak van een valide drempelwaarde is duidelijk, maar nog niet 
vastgesteld. Aangezien circulerend DNA kan worden bepaald met verschillende 
technieken, zoals qPCR, pico green kwantificatie en radioimmunoassay, en met 
verschillende target genen, is het lastig een drempelwaarde te definiëren die 
kan gelden voor alle patiënten met niet-kleincellig longkanker wereldwijd.38-40 
Daarnaast is de betekenis van een DNA concentratie net boven de drempelwaarde 
onduidelijk. Hierdoor kan de DNA concentratie van waarde zijn voor een groep 
patiënten, maar nog niet voor de individuele patiënt. Met de toenemende verfijning 
in predictieve markers en behandeling op maat, kan de rol van circulerend DNA 
als predictieve marker verder worden uitgewerkt. Recent onderzoek laat zien dat 
circulerend DNA voorspellend was in de respons op chemotherapie, maar nog 
niet op doelgerichte therapie.30,37,41,42 
Naast extracellulair DNA kunnen circulerende tumorcellen worden gevonden 
in plasma.43 Studies naar borst-, prostaat- en colorectaal kanker hebben de 
prognostische waarde van circulerende tumorcellen aangetoond. In recent 
onderzoek werd een verhoogd aantal circulerende tumorcellen gevonden 
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bij stadium IV longkankerpatiënten en dit was gecorreleerd aan slechte 
overleving.44,45 Door een variatie aan onderzoeks- en  detectiemethoden in 
verschillende laboratoria is interpretatie van data nog lastig, overeenkomend met 
de extracellulaire DNA studies.  Het blijft een uitdaging in toekomstig onderzoek 
om de grenzen van klinische mogelijkheden van zowel circulerend DNA als 
circulerende tumorcellen op te sporen. 
Bevolkingsonderzoek naar overleving van longkanker
Naast de prognostische waarde van circulerend plasma DNA voor de overleving 
van longkankerpatiënten, waren veranderingen in overleving ten gevolge van 
veranderingen in behandeling in de laatste 20 jaar onderdeel van dit proefschrift. 
De relatieve 5-jaarsoverleving van alle patiënten met niet-kleincellig longkanker 
in Nederland is licht verbeterd sinds 2004/5. Bij kleincellig longkanker verbeterde 
de relatieve 1-jaars overleving van patiënten tussen 45-59 jaar, maar niet voor 
de andere leeftijdsgroepen. Stadiummigratie heeft bijgedragen aan de kleine 
veranderingen in overleving in alle stadia.46 Daarnaast heeft betere naleving van 
behandelingen volgens klinische standaarden zoals richtlijnen bijgedragen aan 
verbeterde overleving op bevolkingsnivo.47 Hoewel de toepassing van standaard 
behandeling in de laatste jaren is toegenomen, bleef dit significant achter voor 
ouderen. Zowel uitkomsten van behandeling als overleving in klinische studies, 
die vooral jongere patiënten met een goede performance status includeren, 
staan nog ver af van de toepassing van behandeling en overlevingsresultaten 
van ongeselecteerde patiënten in de dagelijkse praktijk. We bevinden ons hier 
op het grensgebied van evidence-based medicine en patiënt-based medicine. De 
individuele therapiekeuze van ouderen, onder andere gebaseerd op comorbiditeit 
en kwaliteit van leven, begrenst bij hen de overleving. Daarentegen wordt de 
optimale overleving van jongeren meer geleid door strikte behandelprotocollen.
Naast het onderzoek naar een veelvoud van moleculaire biomarkers als 
prognostische en predictieve factoren voor overleving, worden nieuwe 
behandelstrategiëen op maat ontwikkeld en handelen artsen in toenemende 
mate volgens de laatste richtlijnen. Bovendien zijn artsen en onderzoekers zich 
toenemend bewust van het positieve effect van psychosociale en palliatieve 
zorg op de overleving.48 Gemetastaseerd longkanker leidt tot een hoge 
symptoomlast en slechte kwaliteit van leven. In de palliatieve zorg, met het focus 
op het management van symptomen, psychosociale ondersteuning, en hulp in de 
besluitvorming, kan de kwaliteit van zorg worden verbeterd resulterend in minder 
depressieve symptomen en een lager gebruik van medische diensten. Optimale 
integratie van psychosociale ondersteuning en palliatieve zorg met standaard 
oncologische zorg bij patiënten met longkanker moet het focus zijn van de klinisch 
oncologische praktijk en toekomstig onderzoek.
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Nawoord: een weg van dankbaarheid
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Dank aan de pathologen van het CWZ voor de analyses en in het bijzonder Clemens 
Prinsen. Heel fijn hoe geduldig je mij alle moeilijke DNA analyses uitlegde.
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klinische invalshoek. Veel dank ook aan de coauteurs van de epidemiologische 
studies en in het bijzonder Henrike Karim-Kos en Maryska Janssen-Heijnen voor 
het inspirerende overleg. 
Ook dank ik mijn collega-longartsen in het Radboud en in het bijzonder Dekkerswald 
voor de mogelijkheid tijd vrij te maken om te kunnen werken aan dit proefschrift. 
Heel wat uren  patiëntenzorg zijn door jullie opgevangen, vooral door Monique 
Reijers en Chantal Smits-van der Graaf, aan wie ik deze zorg vol vertrouwen kon 
overlaten. In de beginjaren deelde ik met genoegen een kamer met Anja Timmer-
Bonte met wie ik de oncologische zorg in Dekkerswald vorm heb kunnen geven. Ik
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locatie met rustige en warme uitstraling, korte lijnen en persoonlijke inzet van 
alle medewerkers voor de (oncologische) patiënten. In het Radboud vervolgt mijn 
weg zich en ik verheug mij op de vruchten die de intensievere samenwerking 
met Olga Schuurbiers, Erik van der Heijden en Chantal op oncologisch gebied zal 
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Desiree van den Hurk, wat een tomeloze en warme inzet heb je voor de 
oncologische patiënten. Jij hebt heel wat patiëntenzorg van mij overgenomen en 
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voor jou in het vooruitzicht. Dank voor je vertrouwen en warme samenwerking. 
Theo Hafmans, veel dank voor je inzet bij de lay-out van dit proefschrift.
Ook in persoonlijk opzicht beschouw ik dit proefschrift niet als een eindproduct, 
maar een stap verder in mijn persoonlijke groei en ontwikkeling. De rust, wijsheid 
en inzicht die ik met mindfulness ontwikkel, vormen een goed tegenwicht voor 
het drukke, prestatiegerichte leven, waardoor ik in balans blijf. Wat geniet ik van 
de opleiding tot mindfulnesstrainer. Ik ben ook de volgende personen oprecht 
dankbaar.
Joske van Huygevoort, nog vaak denk ik terug aan je inzichtgevende gesprekken 
en warme steun. Veel dank dat je op mijn pad meeliep.
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